Raras
Buscar doenças, sintomas, genes...
Miopatia mitocondrial
ORPHA:206966CID-10 · G71.3CID-11 · 8C73DOENÇA RARA

Miocardiopatia causada por problemas nas mitocôndrias.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Miocardiopatia causada por problemas nas mitocôndrias.

Pesquisas ativas
6 ensaios
90 total registrados no ClinicalTrials.gov
Publicações científicas
2.043 artigos
Último publicado: 2026 Apr 30
🏥
SUS: Cobertura mínimaScore: 15%
CID-10: G71.3
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (2)
0202010694
Sequenciamento completo do exoma (WES)genetic_test
0301070040
Atendimento em reabilitação — doenças rarasrehabilitation
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
107 sintomas
💪
Músculos
69 sintomas
❤️
Coração
35 sintomas
🫃
Digestivo
34 sintomas
😀
Face
29 sintomas
👁️
Olhos
28 sintomas

+ 245 sintomas em outras categorias

Características mais comuns

Aumento do piruvato sérico
Reflexo primitivo
Deformidade em equinovaro
Fraqueza muscular distal progressiva
Esteatose hepática difusa
Calafrios
648sintomas
Sem dados (648)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 648 características clínicas mais associadas, ordenadas por frequência.

Aumento do piruvato séricoIncreased serum pyruvate
Reflexo primitivoPrimitive reflex
Deformidade em equinovaroEquinovarus deformity
Fraqueza muscular distal progressivaProgressive distal muscle weakness
Esteatose hepática difusaDiffuse hepatic steatosis

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico2.043PubMed
Últimos 10 anos200publicações
Pico202556 papers
Linha do tempo
2026Hoje · 2026🧪 1978Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

53 genes identificados com associação a esta condição.

SDHASuccinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Flavoprotein (FP) subunit of succinate dehydrogenase (SDH) that is involved in complex II of the mitochondrial electron transport chain and is responsible for transferring electrons from succinate to ubiquinone (coenzyme Q) (PubMed:10746566, PubMed:24781757). SDH also oxidizes malate to the non-canonical enol form of oxaloacetate, enol-oxaloacetate (By similarity). Enol-oxaloacetate, which is a potent inhibitor of the succinate dehydrogenase activity, is further isomerized into keto-oxaloacetate

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (1)
Maturation of TCA enzymes and regulation of TCA cycle
MECANISMO DE DOENÇA

Mitochondrial complex II deficiency, nuclear type 1

A disorder of the mitochondrial respiratory chain with heterogeneous clinical manifestations. Clinical features include psychomotor regression in infants, poor growth with lack of speech development, severe spastic quadriplegia, dystonia, progressive leukoencephalopathy, muscle weakness, exercise intolerance, cardiomyopathy. Some patients manifest Leigh syndrome or Kearns-Sayre syndrome. MC2DN1 inheritance is autosomal recessive.

EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Ventrículo esquerdo
302.0 TPM
Músculo esquelético
237.6 TPM
Coração - Átrio
206.8 TPM
Glândula adrenal
172.2 TPM
Linfócitos
168.3 TPM
OUTRAS DOENÇAS (9)
mitochondrial complex II deficiency, nuclear type 1pheochromocytoma/paraganglioma syndrome 5neurodegeneration with ataxia and late-onset optic atrophydilated cardiomyopathy 1GG
HGNC:10680UniProt:P31040
SCO1Cytochrome c oxidase assembly factor SCO1Candidate gene tested inTolerante
FUNÇÃO

Copper metallochaperone essential for the maturation of cytochrome c oxidase subunit II (MT-CO2/COX2). Together with SCO2, involved in delivering copper to the Cu(A) site on MT-CO2/COX2 (PubMed:15229189, PubMed:15659396, PubMed:16735468, PubMed:17189203, PubMed:19336478). Plays an important role in the regulation of copper homeostasis by controlling the abundance and cell membrane localization of copper transporter CTR1 (By similarity)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (1)
Complex IV assembly
MECANISMO DE DOENÇA

Mitochondrial complex IV deficiency, nuclear type 4

An autosomal recessive mitochondrial disorder characterized by hypotonia, encephalopathy, metabolic acidosis, poor feeding, hepatomegaly, and hypertrophic cardiomyopathy in some patients. Death occurs in infancy. Patient tissues show decreased levels and activity of mitochondrial respiratory complex IV.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
14.3 TPM
Fibroblastos
13.5 TPM
Cervix Endocervix
10.7 TPM
Útero
10.7 TPM
Tireoide
9.8 TPM
OUTRAS DOENÇAS (2)
mitochondrial complex IV deficiency, nuclear type 4fatal infantile encephalocardiomyopathy
HGNC:10603UniProt:O75880
MT-ATP8ATP synthase F(0) complex subunit 8Candidate gene tested inDesconhecido
FUNÇÃO

Subunit 8, of the mitochondrial membrane ATP synthase complex (F(1)F(0) ATP synthase or Complex V) that produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain (PubMed:37244256). ATP synthase complex consist of a soluble F(1) head domain - the catalytic core - and a membrane F(1) domain - the membrane proton channel (PubMed:37244256). These two domains are linked by a central stalk rotating inside

LOCALIZAÇÃO

Mitochondrion membrane

VIAS BIOLÓGICAS (3)
Mitochondrial translation terminationFormation of ATP by chemiosmotic couplingCristae formation
MECANISMO DE DOENÇA

Mitochondrial complex V deficiency, mitochondrial 2

A mitochondrial disorder with heterogeneous clinical manifestations including neuropathy, ataxia, hypertrophic cardiomyopathy. Hypertrophic cardiomyopathy can present with negligible to extreme hypertrophy, minimal to extensive fibrosis and myocyte disarray, absent to severe left ventricular outflow tract obstruction, and distinct septal contours/morphologies with extremely varying clinical course.

OUTRAS DOENÇAS (4)
mitochondrial diseaseperiodic paralysis with later-onset distal motor neuropathymitochondrial proton-transporting ATP synthase complex deficiencyKearns-Sayre syndrome
HGNC:7415UniProt:P03928
MT-TWCandidate gene tested inDesconhecido
LOCALIZAÇÃO

VIAS BIOLÓGICAS (3)
G alpha (i) signalling eventsFormyl peptide receptors bind formyl peptides and many other ligandsG alpha (q) signalling events
OUTRAS DOENÇAS (3)
mitochondrial diseasematernally-inherited Leigh syndromeMELAS syndrome
HGNC:7501
MT-CO3Cytochrome c oxidase subunit 3Candidate gene tested inDesconhecido
FUNÇÃO

Component of the cytochrome c oxidase, the last enzyme in the mitochondrial electron transport chain which drives oxidative phosphorylation. The respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase (complex IV, CIV), that cooperate to transfer electrons derived from NADH and succinate to molecular oxygen, creating an electrochemical gradient over t

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (5)
Cytoprotection by HMOX1Respiratory electron transportTP53 Regulates Metabolic GenesComplex IV assemblyMitochondrial translation termination
MECANISMO DE DOENÇA

Leber hereditary optic neuropathy

A maternally inherited form of Leber hereditary optic neuropathy, a mitochondrial disease resulting in bilateral painless loss of central vision due to selective degeneration of the retinal ganglion cells and their axons. The disorder shows incomplete penetrance and male predominance. Cardiac conduction defects and neurological defects have also been described in some LHON patients. LHON results from primary mitochondrial DNA mutations affecting the respiratory chain complexes.

OUTRAS DOENÇAS (5)
mitochondrial diseasemitochondrial complex IV deficiency, nuclear-typeMELAS syndromehereditary recurrent myoglobinuria
HGNC:7422UniProt:P00414
MT-CO2Cytochrome c oxidase subunit 2Candidate gene tested inDesconhecido
FUNÇÃO

Component of the cytochrome c oxidase, the last enzyme in the mitochondrial electron transport chain which drives oxidative phosphorylation. The respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase (complex IV, CIV), that cooperate to transfer electrons derived from NADH and succinate to molecular oxygen, creating an electrochemical gradient over t

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (6)
Cytoprotection by HMOX1Respiratory electron transportTP53 Regulates Metabolic GenesComplex IV assemblyMitochondrial translation termination
MECANISMO DE DOENÇA

Mitochondrial complex IV deficiency

A disorder of the mitochondrial respiratory chain with heterogeneous clinical manifestations, ranging from isolated myopathy to severe multisystem disease affecting several tissues and organs. Features include hypertrophic cardiomyopathy, hepatomegaly and liver dysfunction, hypotonia, muscle weakness, exercise intolerance, developmental delay, delayed motor development and intellectual disability. Some affected individuals manifest a fatal hypertrophic cardiomyopathy resulting in neonatal death. A subset of patients manifest Leigh syndrome.

OUTRAS DOENÇAS (3)
mitochondrial diseaseMELAS syndromemitochondrial complex IV deficiency, nuclear-type
HGNC:7421UniProt:P00403
MT-TQCandidate gene tested inDesconhecido
LOCALIZAÇÃO

VIAS BIOLÓGICAS (3)
G alpha (i) signalling eventsFormyl peptide receptors bind formyl peptides and many other ligandsG alpha (q) signalling events
OUTRAS DOENÇAS (2)
MELAS syndromeMERRF syndrome
HGNC:7495
MT-ND4NADH-ubiquinone oxidoreductase chain 4Candidate gene tested inDesconhecido
FUNÇÃO

Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor (PubMed:15250827, PubMed:8344246, PubMed:8644732). Essential for the catalytic activity and assembly of complex I (PubMed:15250827, PubMed:8344246, PubMed:8644732)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (3)
Respiratory electron transportComplex I biogenesisMitochondrial translation termination
MECANISMO DE DOENÇA

Leber hereditary optic neuropathy

A maternally inherited form of Leber hereditary optic neuropathy, a mitochondrial disease resulting in bilateral painless loss of central vision due to selective degeneration of the retinal ganglion cells and their axons. The disorder shows incomplete penetrance and male predominance. Cardiac conduction defects and neurological defects have also been described in some LHON patients. LHON results from primary mitochondrial DNA mutations affecting the respiratory chain complexes.

OUTRAS DOENÇAS (6)
mitochondrial diseasematernally-inherited Leigh syndromeMELAS syndromeLeber plus disease
HGNC:7459UniProt:P03905
MT-CO1Cytochrome c oxidase subunit 1Candidate gene tested inDesconhecido
FUNÇÃO

Component of the cytochrome c oxidase, the last enzyme in the mitochondrial electron transport chain which drives oxidative phosphorylation. The respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase (complex IV, CIV), that cooperate to transfer electrons derived from NADH and succinate to molecular oxygen, creating an electrochemical gradient over t

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (6)
Cytoprotection by HMOX1Respiratory electron transportTP53 Regulates Metabolic GenesComplex IV assemblyMitochondrial translation termination
MECANISMO DE DOENÇA

Leber hereditary optic neuropathy

A maternally inherited form of Leber hereditary optic neuropathy, a mitochondrial disease resulting in bilateral painless loss of central vision due to selective degeneration of the retinal ganglion cells and their axons. The disorder shows incomplete penetrance and male predominance. Cardiac conduction defects and neurological defects have also been described in some LHON patients. LHON results from primary mitochondrial DNA mutations affecting the respiratory chain complexes.

OUTRAS DOENÇAS (6)
mitochondrial diseaseMELAS syndromemitochondrial complex IV deficiency, nuclear-typemitochondrial non-syndromic sensorineural hearing loss
HGNC:7419UniProt:P00395
MT-TS2Candidate gene tested inDesconhecido
LOCALIZAÇÃO

VIAS BIOLÓGICAS (3)
G alpha (i) signalling eventsFormyl peptide receptors bind formyl peptides and many other ligandsG alpha (q) signalling events
OUTRAS DOENÇAS (4)
mitochondrial diseaseMERRF syndromeUsher syndrome type 3MELAS syndrome
HGNC:7498
MT-TL2Candidate gene tested inDesconhecido
LOCALIZAÇÃO

VIAS BIOLÓGICAS (3)
G alpha (i) signalling eventsFormyl peptide receptors bind formyl peptides and many other ligandsG alpha (q) signalling events
OUTRAS DOENÇAS (3)
mitochondrial diseasematernally-inherited progressive external ophthalmoplegiaalternating hemiplegia of childhood
HGNC:7491
MT-TL1Candidate gene tested inDesconhecido
LOCALIZAÇÃO

VIAS BIOLÓGICAS (3)
G alpha (i) signalling eventsFormyl peptide receptors bind formyl peptides and many other ligandsG alpha (q) signalling events
OUTRAS DOENÇAS (7)
mitochondrial diseasematernally-inherited Leigh syndromeMELAS syndromeMERRF syndrome
HGNC:7490
MT-TTCandidate gene tested inDesconhecido
LOCALIZAÇÃO

VIAS BIOLÓGICAS (3)
G alpha (i) signalling eventsFormyl peptide receptors bind formyl peptides and many other ligandsG alpha (q) signalling events
OUTRAS DOENÇAS (2)
mitochondrial diseaselethal infantile mitochondrial myopathy
HGNC:7499
TRMUMitochondrial tRNA-specific 2-thiouridylase 1Candidate gene tested inTolerante
FUNÇÃO

Catalyzes the 2-thiolation of uridine at the wobble position (U34) of mitochondrial tRNA(Lys), tRNA(Glu) and tRNA(Gln). Required for the formation of 5-taurinomethyl-2-thiouridine (tm5s2U) of mitochondrial tRNA(Lys), tRNA(Glu), and tRNA(Gln) at the wobble position. ATP is required to activate the C2 atom of the wobble base

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
tRNA modification in the mitochondrion
MECANISMO DE DOENÇA

Deafness, aminoglycoside-induced

A form of sensorineural deafness characterized by moderate-to-profound hearing loss and mitochondrial inheritance. It is induced by exposure to aminoglycosides.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
22.9 TPM
Cérebro - Hemisfério cerebelar
21.9 TPM
Linfócitos
20.7 TPM
Cervix Endocervix
19.9 TPM
Pituitária
19.9 TPM
INTERAÇÕES PROTEICAS (5)
OUTRAS DOENÇAS (4)
acute infantile liver failure due to synthesis defect of mtDNA-encoded proteinsmitochondrial myopathy with reversible cytochrome C oxidase deficiencymitochondrial non-syndromic sensorineural hearing lossdeafness, aminoglycoside-induced
HGNC:25481UniProt:O75648
MT-TECandidate gene tested inDesconhecido
LOCALIZAÇÃO

VIAS BIOLÓGICAS (3)
G alpha (i) signalling eventsFormyl peptide receptors bind formyl peptides and many other ligandsG alpha (q) signalling events
OUTRAS DOENÇAS (3)
mitochondrial diseasemitochondrial myopathy with reversible cytochrome C oxidase deficiencymitochondrial myopathy with diabetes
HGNC:7479
MT-ND5NADH-ubiquinone oxidoreductase chain 5Candidate gene tested inDesconhecido
FUNÇÃO

Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor (PubMed:15250827). Essential for the catalytic activity and assembly of complex I (PubMed:15250827)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (4)
Respiratory electron transportComplex I biogenesisMitochondrial translation terminationMitochondrial protein degradation
MECANISMO DE DOENÇA

Leber hereditary optic neuropathy

A maternally inherited form of Leber hereditary optic neuropathy, a mitochondrial disease resulting in bilateral painless loss of central vision due to selective degeneration of the retinal ganglion cells and their axons. The disorder shows incomplete penetrance and male predominance. Cardiac conduction defects and neurological defects have also been described in some LHON patients. LHON results from primary mitochondrial DNA mutations affecting the respiratory chain complexes.

OUTRAS DOENÇAS (5)
mitochondrial diseaseMELAS syndromematernally-inherited Leigh syndromeMERRF syndrome
HGNC:7461UniProt:P03915
MT-TKCandidate gene tested inDesconhecido
LOCALIZAÇÃO

VIAS BIOLÓGICAS (3)
G alpha (i) signalling eventsFormyl peptide receptors bind formyl peptides and many other ligandsG alpha (q) signalling events
OUTRAS DOENÇAS (4)
mitochondrial diseaseMERRF syndromematernally-inherited cardiomyopathy and hearing lossmaternally-inherited Leigh syndrome
HGNC:7489
AMPD3AMP deaminase 3Candidate gene tested inTolerante
FUNÇÃO

AMP deaminase plays a critical role in energy metabolism

LOCALIZAÇÃO

VIAS BIOLÓGICAS (1)
Purine salvage
MECANISMO DE DOENÇA

Adenosine monophosphate deaminase deficiency erythrocyte type

A metabolic disorder due to lack of activity of the erythrocyte isoform of AMP deaminase. It is a clinically asymptomatic condition characterized by a 50% increase in steady-state levels of ATP in affected cells. Individuals with complete deficiency of erythrocyte AMP deaminase are healthy and have no hematologic disorders.

OUTRAS DOENÇAS (2)
obsolete erythrocyte AMP deaminase deficiencyadenosine monophosphate deaminase deficiency
HGNC:470UniProt:Q01432
MT-ND1NADH-ubiquinone oxidoreductase chain 1Candidate gene tested inDesconhecido
FUNÇÃO

Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor (PubMed:1959619). Essential for the catalytic activity and assembly of complex I (PubMed:1959619, PubMed:26929434)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (4)
Respiratory electron transportComplex I biogenesisMitochondrial translation terminationMitochondrial protein degradation
MECANISMO DE DOENÇA

Leber hereditary optic neuropathy

A maternally inherited form of Leber hereditary optic neuropathy, a mitochondrial disease resulting in bilateral painless loss of central vision due to selective degeneration of the retinal ganglion cells and their axons. The disorder shows incomplete penetrance and male predominance. Cardiac conduction defects and neurological defects have also been described in some LHON patients. LHON results from primary mitochondrial DNA mutations affecting the respiratory chain complexes.

OUTRAS DOENÇAS (5)
mitochondrial diseaseMELAS syndromemitochondrial complex I deficiencymaternally-inherited Leigh syndrome
HGNC:7455UniProt:P03886
MT-TFCandidate gene tested inDesconhecido
LOCALIZAÇÃO

VIAS BIOLÓGICAS (2)
Post-translational protein phosphorylationRegulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
OUTRAS DOENÇAS (4)
mitochondrial diseaseMELAS syndromeGitelman-like kidney tubulopathy due to mitochondrial DNA mutationMERRF syndrome
HGNC:7481
MT-THCandidate gene tested inDesconhecido
LOCALIZAÇÃO

VIAS BIOLÓGICAS (1)
Catecholamine biosynthesis
OUTRAS DOENÇAS (4)
mitochondrial diseaseMERRF syndromeMELAS syndromemitochondrial non-syndromic sensorineural hearing loss
HGNC:7487
MT-TS1Candidate gene tested inDesconhecido
LOCALIZAÇÃO

VIAS BIOLÓGICAS (3)
G alpha (i) signalling eventsFormyl peptide receptors bind formyl peptides and many other ligandsG alpha (q) signalling events
OUTRAS DOENÇAS (6)
mitochondrial diseaseMERRF syndromepalmoplantar keratoderma-deafness syndromematernally-inherited progressive external ophthalmoplegia
HGNC:7497
MSTO1Protein misato homolog 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Involved in the regulation of mitochondrial distribution and morphology (PubMed:17349998, PubMed:28544275, PubMed:28554942). Required for mitochondrial fusion and mitochondrial network formation (PubMed:28544275, PubMed:28554942)

LOCALIZAÇÃO

Mitochondrion outer membraneCytoplasm

MECANISMO DE DOENÇA

Myopathy, mitochondrial, and ataxia

A neuromuscular disorder characterized by muscle weakness and atrophy, ataxia, poor growth, delayed motor development, dysdiadochokinesia, dysmetria and additional neurologic features. Some patients show skeletal and endocrine anomalies, as well as behavioral psychiatric manifestations. MMYAT transmission pattern is consistent with autosomal dominant inheritance in some families, and autosomal recessive inheritance in others.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
35.2 TPM
Nervo tibial
17.4 TPM
Ovário
15.4 TPM
Útero
15.3 TPM
Pituitária
15.3 TPM
OUTRAS DOENÇAS (1)
mitochondrial myopathy-cerebellar ataxia-pigmentary retinopathy syndrome
HGNC:29678UniProt:Q9BUK6
HADHATrifunctional enzyme subunit alpha, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Mitochondrial trifunctional enzyme catalyzes the last three of the four reactions of the mitochondrial beta-oxidation pathway (PubMed:1550553, PubMed:29915090, PubMed:30850536, PubMed:8135828, PubMed:31604922). The mitochondrial beta-oxidation pathway is the major energy-producing process in tissues and is performed through four consecutive reactions breaking down fatty acids into acetyl-CoA (PubMed:29915090). Among the enzymes involved in this pathway, the trifunctional enzyme exhibits specific

LOCALIZAÇÃO

MitochondrionMitochondrion inner membrane

VIAS BIOLÓGICAS (8)
Acyl chain remodeling of CLBeta oxidation of hexanoyl-CoA to butanoyl-CoABeta oxidation of octanoyl-CoA to hexanoyl-CoABeta oxidation of decanoyl-CoA to octanoyl-CoA-CoABeta oxidation of lauroyl-CoA to decanoyl-CoA-CoA
MECANISMO DE DOENÇA

Mitochondrial trifunctional protein deficiency 1

An autosomal recessive metabolic disorder of long-chain fatty acid oxidation, biochemically characterized by loss of all enzyme activities of the mitochondrial trifunctional protein complex. The disease phenotype ranges from a fatal form characterized by early-onset cardiomyopathy, cardiac failure and early death to less severe, late-onset forms with myopathy, recurrent rhabdomyolysis, and sensorimotor axonal neuropathy as key features.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
343.5 TPM
Coração - Ventrículo esquerdo
215.7 TPM
Linfócitos
203.7 TPM
Fibroblastos
194.0 TPM
Esôfago - Muscular
182.5 TPM
OUTRAS DOENÇAS (4)
long chain 3-hydroxyacyl-CoA dehydrogenase deficiencymitochondrial trifunctional protein deficiency 1mitochondrial trifunctional protein deficiencyacute fatty liver of pregnancy
HGNC:4801UniProt:P40939
FDX2Ferredoxin-2, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Electron donor, of the core iron-sulfur cluster (ISC) assembly complex, that acts to reduce the persulfide into sulfide during [2Fe-2S] clusters assembly on the scaffolding protein ISCU (PubMed:28001042). The core iron-sulfur cluster (ISC) assembly complex is involved in the de novo synthesis of a [2Fe-2S] cluster, the first step of the mitochondrial iron-sulfur protein biogenesis (By similarity). This process is initiated by the cysteine desulfurase complex (NFS1:LYRM4:NDUFAB1) that produces pe

LOCALIZAÇÃO

MitochondrionMitochondrion matrix

VIAS BIOLÓGICAS (5)
Mitochondrial iron-sulfur cluster biogenesisElectron transport from NADPH to FerredoxinEndogenous sterolsPregnenolone biosynthesisDefective CYP11A1 causes AICSR
MECANISMO DE DOENÇA

Mitochondrial myopathy, episodic, with optic atrophy and reversible leukoencephalopathy

An autosomal recessive neuromuscular disorder characterized by childhood onset of recurrent episodes of proximal weakness and myalgia often precipitated by exercise, infections or low temperature. Additional features are optic atrophy, axonal polyneuropathy, and reversible or partially reversible leukoencephalopathy.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Frontal Cortex BA9
62.2 TPM
Córtex cerebral
54.1 TPM
Brain Anterior cingulate cortex BA24
52.7 TPM
Brain Nucleus accumbens basal ganglia
43.9 TPM
Tireoide
41.0 TPM
OUTRAS DOENÇAS (1)
mitochondrial myopathy, episodic, with optic atrophy and reversible leukoencephalopathy
HGNC:HGNC:30546UniProt:Q6P4F2
SDHBSuccinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Iron-sulfur protein (IP) subunit of the succinate dehydrogenase complex (mitochondrial respiratory chain complex II), responsible for transferring electrons from succinate to ubiquinone (coenzyme Q) (PubMed:26925370, PubMed:27604842). SDH also oxidizes malate to the non-canonical enol form of oxaloacetate, enol-oxaloacetate (By similarity). Enol-oxaloacetate, which is a potent inhibitor of the succinate dehydrogenase activity, is further isomerized into keto-oxaloacetate (By similarity)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (1)
Maturation of TCA enzymes and regulation of TCA cycle
MECANISMO DE DOENÇA

Pheochromocytoma/paraganglioma syndrome 4

A form of pheochromocytoma/paraganglioma syndrome, a tumor predisposition syndrome characterized by the development of neuroendocrine tumors, usually in adulthood. Pheochromocytomas are catecholamine-producing tumors that arise from chromaffin cells in the adrenal medulla. Paragangliomas develop from sympathetic paraganglia in the thorax, abdomen, and pelvis, as well as from parasympathetic paraganglia in the head and neck. PPGL4 inheritance is autosomal dominant.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
177.6 TPM
Coração - Ventrículo esquerdo
168.2 TPM
Linfócitos
144.5 TPM
Fígado
124.9 TPM
Coração - Átrio
122.8 TPM
OUTRAS DOENÇAS (9)
Carney-Stratakis syndromepheochromocytoma/paraganglioma syndrome 4gastrointestinal stromal tumormitochondrial complex 2 deficiency, nuclear type 4
HGNC:10681UniProt:P21912
SDHDSuccinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrialDisease-causing germline mutation(s) inRestrito
FUNÇÃO

Membrane-anchoring subunit of succinate dehydrogenase (SDH) that is involved in complex II of the mitochondrial electron transport chain and is responsible for transferring electrons from succinate to ubiquinone (coenzyme Q) (PubMed:10482792, PubMed:9533030). SDH also oxidizes malate to the non-canonical enol form of oxaloacetate, enol-oxaloacetate (By similarity). Enol-oxaloacetate, which is a potent inhibitor of the succinate dehydrogenase activity, is further isomerized into keto-oxaloacetate

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (3)
Maturation of TCA enzymes and regulation of TCA cycleCitric acid cycle (TCA cycle)Respiratory electron transport
MECANISMO DE DOENÇA

Pheochromocytoma/paraganglioma syndrome 1

A form of pheochromocytoma/paraganglioma syndrome, a tumor predisposition syndrome characterized by the development of neuroendocrine tumors, usually in adulthood. Pheochromocytomas are catecholamine-producing tumors that arise from chromaffin cells in the adrenal medulla. Paragangliomas develop from sympathetic paraganglia in the thorax, abdomen, and pelvis, as well as from parasympathetic paraganglia in the head and neck. PPGL1 inheritance is autosomal dominant.

EXPRESSÃO TECIDUAL(Ubíquo)
Rim - Medula
91.4 TPM
Músculo esquelético
85.3 TPM
Cólon transverso
81.0 TPM
Cólon sigmoide
78.9 TPM
Linfócitos
75.5 TPM
OUTRAS DOENÇAS (8)
Carney-Stratakis syndromepheochromocytoma/paraganglioma syndrome 1mitochondrial complex 2 deficiency, nuclear type 3sporadic pheochromocytoma/secreting paraganglioma
HGNC:10683UniProt:O14521
COA5Cytochrome c oxidase assembly factor 5Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Assembly factor for cytochrome c oxidase (respiratory chain complex IV) (PubMed:21457908, PubMed:35750769). Stabilizes an early formation of cytochrome c oxidase assembly factors, until it is displaced by the metallochaperone copper-delivery protein COX17 (PubMed:35750769)

LOCALIZAÇÃO

Mitochondrion intermembrane space

VIAS BIOLÓGICAS (1)
Complex IV assembly
MECANISMO DE DOENÇA

Mitochondrial complex IV deficiency, nuclear type 9

An autosomal recessive, infantile disorder with a fatal course in the first weeks of life, and characterized by hypertrophic cardiomyopathy and mitochondrial complex IV deficiency. Postmortem microscopic investigations show accumulation of lipid droplets in cardiomyocytes and mitochondrial proliferation.

VIAS REACTOME (1)
OUTRAS DOENÇAS (2)
cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 3fatal infantile encephalocardiomyopathy
HGNC:33848UniProt:Q86WW8
TAFAZZINTafazzinDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Acyltransferase required to remodel newly synthesized phospholipid cardiolipin (1',3'-bis-[1,2-diacyl-sn-glycero-3-phospho]-glycerol or CL), a key component of the mitochondrial inner membrane, with tissue specific acyl chains necessary for adequate mitochondrial function (PubMed:12930833, PubMed:19164547, PubMed:19700766, PubMed:26908608, PubMed:33096711). Its role in cellular physiology is to improve mitochondrial performance (PubMed:32234310). CL is critical for the coassembly of lipids and p

LOCALIZAÇÃO

Mitochondrion outer membraneMitochondrion inner membraneMitochondrion membraneCytoplasm

VIAS BIOLÓGICAS (2)
Acyl chain remodeling of CLMitochondrial protein import
MECANISMO DE DOENÇA

Barth syndrome

An X-linked disease characterized by dilated cardiomyopathy with endocardial fibroelastosis, a predominantly proximal skeletal myopathy, growth retardation, neutropenia, and organic aciduria, particularly excess of 3-methylglutaconic acid. Additional features include hypertrophic cardiomyopathy, isolated left ventricular non-compaction, ventricular arrhythmia, motor delay, poor appetite, fatigue and exercise intolerance, hypoglycemia, lactic acidosis, hyperammonemia, and dramatic late catch-up growth after growth delay throughout childhood.

OUTRAS DOENÇAS (2)
Barth syndromefamilial isolated dilated cardiomyopathy
HGNC:11577UniProt:Q16635
CHCHD10Coiled-coil-helix-coiled-coil-helix domain-containing protein 10, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

May be involved in the maintenance of mitochondrial organization and mitochondrial cristae structure

LOCALIZAÇÃO

Mitochondrion intermembrane space

VIAS BIOLÓGICAS (1)
Mitochondrial protein import
MECANISMO DE DOENÇA

Frontotemporal dementia and/or amyotrophic lateral sclerosis 2

A neurodegenerative disorder characterized by frontotemporal dementia and/or amyotrophic lateral sclerosis in affected individuals. There is high intrafamilial variation. Frontotemporal dementia is characterized by frontal and temporal lobe atrophy associated with neuronal loss, gliosis, and dementia. Patients exhibit progressive changes in social, behavioral, and/or language function. Amyotrophic lateral sclerosis is characterized by the death of motor neurons in the brain, brainstem, and spinal cord, resulting in fatal paralysis.

OUTRAS DOENÇAS (5)
lower motor neuron syndrome with late-adult onsetfrontotemporal dementia and/or amyotrophic lateral sclerosis 2autosomal dominant mitochondrial myopathy with exercise intoleranceamyotrophic lateral sclerosis
HGNC:15559UniProt:Q8WYQ3
TK2Thymidine kinase 2, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Phosphorylates thymidine, deoxycytidine, and deoxyuridine in the mitochondrial matrix (PubMed:11687801, PubMed:9989599). In non-replicating cells, where cytosolic dNTP synthesis is down-regulated, mtDNA synthesis depends solely on TK2 and DGUOK (PubMed:9989599). Widely used as target of antiviral and chemotherapeutic agents (PubMed:9989599)

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
Pyrimidine salvage
MECANISMO DE DOENÇA

Mitochondrial DNA depletion syndrome 2

A disorder due to mitochondrial dysfunction characterized by childhood onset of muscle weakness associated with depletion of mtDNA in skeletal muscle. There is wide clinical variability; some patients have onset in infancy and show a rapidly progressive course with early death due to respiratory failure, whereas others have later onset of a slowly progressive myopathy.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
39.7 TPM
Nervo tibial
33.3 TPM
Tecido adiposo
32.0 TPM
Ovário
28.1 TPM
Fibroblastos
26.0 TPM
OUTRAS DOENÇAS (3)
progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 3mitochondrial DNA depletion syndrome, myopathic formautosomal recessive progressive external ophthalmoplegia
HGNC:11831UniProt:O00142
DGUOKDeoxyguanosine kinase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Phosphorylates deoxyguanosine and deoxyadenosine in the mitochondrial matrix, with the highest efficiency for deoxyguanosine (PubMed:11687801, PubMed:17073823, PubMed:23043144, PubMed:8692979, PubMed:8706825). In non-replicating cells, where cytosolic dNTP synthesis is down-regulated, mtDNA synthesis depends solely on DGUOK and TK2. Phosphorylates certain nucleoside analogs (By similarity). Widely used as target of antiviral and chemotherapeutic agents

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
Purine salvage
MECANISMO DE DOENÇA

Mitochondrial DNA depletion syndrome 3

A disorder due to mitochondrial dysfunction characterized by onset in infancy of progressive liver failure, hypoglycemia, increased lactate in body fluids, and neurologic abnormalities including hypotonia, encephalopathy, peripheral neuropathy. Affected tissues show both decreased activity of the mtDNA-encoded respiratory chain complexes and mtDNA depletion.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
78.1 TPM
Pituitária
72.5 TPM
Ovário
63.9 TPM
Aorta
61.4 TPM
Testículo
61.4 TPM
OUTRAS DOENÇAS (3)
mitochondrial DNA depletion syndrome 3 (hepatocerebral type)portal hypertension, noncirrhotic, 1progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 4
HGNC:2858UniProt:Q16854
SLC25A4ADP/ATP translocase 1Disease-causing germline mutation(s) inModerado
FUNÇÃO

ADP:ATP antiporter that mediates import of ADP into the mitochondrial matrix for ATP synthesis, and export of ATP out to fuel the cell (PubMed:21586654, PubMed:27693233, PubMed:23173940, PubMed:30046662). Cycles between the cytoplasmic-open state (c-state) and the matrix-open state (m-state): operates by the alternating access mechanism with a single substrate-binding site intermittently exposed to either the cytosolic (c-state) or matrix (m-state) side of the inner mitochondrial membrane (By si

LOCALIZAÇÃO

Mitochondrion inner membraneMembrane

VIAS BIOLÓGICAS (1)
Mitochondrial protein import
MECANISMO DE DOENÇA

Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 2

A disorder characterized by progressive weakness of ocular muscles and levator muscle of the upper eyelid. In a minority of cases, it is associated with skeletal myopathy, which predominantly involves axial or proximal muscles and which causes abnormal fatigability and even permanent muscle weakness. Ragged-red fibers and atrophy are found on muscle biopsy. A large proportion of chronic ophthalmoplegias are associated with other symptoms, leading to a multisystemic pattern of this disease. Additional symptoms are variable, and may include cataracts, hearing loss, sensory axonal neuropathy, ataxia, depression, hypogonadism, and parkinsonism.

EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Ventrículo esquerdo
563.9 TPM
Coração - Átrio
428.0 TPM
Músculo esquelético
370.5 TPM
Cérebro - Hemisfério cerebelar
138.9 TPM
Esôfago - Muscular
110.1 TPM
OUTRAS DOENÇAS (5)
mitochondrial DNA depletion syndrome 12B (cardiomyopathic type), autosomal recessivemitochondrial DNA depletion syndrome 12A (cardiomyopathic type), autosomal dominantprogressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 2autosomal dominant progressive external ophthalmoplegia
HGNC:10990UniProt:P12235
RRM1Ribonucleoside-diphosphate reductase large subunitDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (1)
Interconversion of nucleotide di- and triphosphates
MECANISMO DE DOENÇA

Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 6

A form of progressive external ophthalmoplegia, a mitochondrial myopathy characterized by progressive paralysis of the levator palpebrae, orbicularis oculi, and extraocular muscles. Ragged red fibers are seen on muscle biopsy.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
104.0 TPM
Fibroblastos
56.4 TPM
Skin Sun Exposed Lower leg
47.0 TPM
Skin Not Sun Exposed Suprapubic
42.4 TPM
Vagina
32.8 TPM
OUTRAS DOENÇAS (2)
progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal recessive 6autosomal recessive progressive external ophthalmoplegia
HGNC:10451UniProt:P23921
RNASEH1Ribonuclease H1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Endonuclease that specifically degrades the RNA of RNA-DNA hybrids (PubMed:10497183). Plays a role in RNA polymerase II (RNAp II) transcription termination by degrading R-loop RNA-DNA hybrid formation at G-rich pause sites located downstream of the poly(A) site and behind the elongating RNAp II (PubMed:21700224)

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (1)
Strand-asynchronous mitochondrial DNA replication
MECANISMO DE DOENÇA

Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 2

A form of progressive external ophthalmoplegia, a mitochondrial myopathy characterized by progressive paralysis of the levator palpebrae, orbicularis oculi, and extraocular muscles. PEOB2 patients manifest exercise intolerance, muscle weakness, and signs and symptoms of spinocerebellar ataxia, such as impaired gait and dysarthria. Some patients may have respiratory insufficiency.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
33.3 TPM
Linfócitos
28.8 TPM
Artéria tibial
17.2 TPM
Útero
16.7 TPM
Nervo tibial
15.5 TPM
OUTRAS DOENÇAS (2)
progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 2adult-onset chronic progressive external ophthalmoplegia with mitochondrial myopathy
HGNC:18466UniProt:O60930
RRM2BRibonucleoside-diphosphate reductase subunit M2 BDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Plays a pivotal role in cell survival by repairing damaged DNA in a p53/TP53-dependent manner. Supplies deoxyribonucleotides for DNA repair in cells arrested at G1 or G2. Contains an iron-tyrosyl free radical center required for catalysis. Forms an active ribonucleotide reductase (RNR) complex with RRM1 which is expressed both in resting and proliferating cells in response to DNA damage

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (2)
TP53 Regulates Metabolic GenesInterconversion of nucleotide di- and triphosphates
MECANISMO DE DOENÇA

Mitochondrial DNA depletion syndrome 8A

A disorder due to mitochondrial dysfunction characterized by various combinations of neonatal hypotonia, neurological deterioration, respiratory distress, lactic acidosis, and renal tubulopathy.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
35.2 TPM
Tireoide
33.1 TPM
Fibroblastos
25.4 TPM
Aorta
22.0 TPM
Pulmão
20.7 TPM
OUTRAS DOENÇAS (7)
progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 5rod-cone dystrophy, sensorineural deafness, and Fanconi-type renal dysfunctionmitochondrial DNA depletion syndrome 8aKearns-Sayre syndrome
HGNC:17296UniProt:Q7LG56
SDHAF1Succinate dehydrogenase assembly factor 1, mitochondrialDisease-causing germline mutation(s) inDesconhecido
FUNÇÃO

Plays an essential role in the assembly of succinate dehydrogenase (SDH), an enzyme complex (also referred to as respiratory complex II) that is a component of both the tricarboxylic acid (TCA) cycle and the mitochondrial electron transport chain, and which couples the oxidation of succinate to fumarate with the reduction of ubiquinone (coenzyme Q) to ubiquinol (PubMed:19465911, PubMed:24954417). Promotes maturation of the iron-sulfur protein subunit SDHB of the SDH catalytic dimer, protecting i

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (1)
Maturation of TCA enzymes and regulation of TCA cycle
MECANISMO DE DOENÇA

Mitochondrial complex II deficiency, nuclear type 2

A form of mitochondrial complex II deficiency, a disorder with heterogeneous clinical manifestations. Some patients have multisystem involvement of the brain, heart, muscle, liver, and kidneys resulting in death in infancy, whereas others have only isolated cardiac or muscle involvement with onset in adulthood and normal cognition. Clinical features include psychomotor regression in infants, poor growth with lack of speech development, severe spastic quadriplegia, dystonia, progressive leukoencephalopathy, muscle weakness, exercise intolerance, cardiomyopathy. Some patients manifest Leigh syndrome or Kearns-Sayre syndrome. MC2DN2 inheritance is autosomal recessive.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
56.9 TPM
Cerebelo
49.9 TPM
Cervix Endocervix
38.4 TPM
Fallopian Tube
37.5 TPM
Cervix Ectocervix
36.7 TPM
OUTRAS DOENÇAS (2)
mitochondrial complex 2 deficiency, nuclear type 2mitochondrial complex II deficiency, nuclear type 1
HGNC:33867UniProt:A6NFY7
GFERFAD-linked sulfhydryl oxidase ALRDisease-causing germline mutation(s) inTolerante
FUNÇÃO

FAD-dependent sulfhydryl oxidase that regenerates the redox-active disulfide bonds in CHCHD4/MIA40, a chaperone essential for disulfide bond formation and protein folding in the mitochondrial intermembrane space. The reduced form of CHCHD4/MIA40 forms a transient intermolecular disulfide bridge with GFER/ERV1, resulting in regeneration of the essential disulfide bonds in CHCHD4/MIA40, while GFER/ERV1 becomes re-oxidized by donating electrons to cytochrome c or molecular oxygen May act as an auto

LOCALIZAÇÃO

Mitochondrion intermembrane spaceMitochondrionCytoplasmSecreted

VIAS BIOLÓGICAS (1)
Mitochondrial protein import
MECANISMO DE DOENÇA

Myopathy, mitochondrial progressive, with congenital cataract, hearing loss and developmental delay

A disease characterized by progressive myopathy and partial combined respiratory-chain deficiency, congenital cataract, sensorineural hearing loss, and developmental delay.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
39.4 TPM
Cérebro - Hemisfério cerebelar
39.0 TPM
Testículo
26.9 TPM
Intestino delgado
22.8 TPM
Cólon transverso
22.1 TPM
OUTRAS DOENÇAS (1)
congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome
HGNC:4236UniProt:P55789
PNPLA8Calcium-independent phospholipase A2-gammaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Calcium-independent and membrane-bound phospholipase, that catalyzes the esterolytic cleavage of fatty acids from glycerophospholipids to yield free fatty acids and lysophospholipids, hence regulating membrane physical properties and the release of lipid second messengers and growth factors (PubMed:10744668, PubMed:10833412, PubMed:15695510, PubMed:15908428, PubMed:17213206, PubMed:18171998, PubMed:28442572). Hydrolyzes phosphatidylethanolamine, phosphatidylcholine and probably phosphatidylinosi

LOCALIZAÇÃO

Endoplasmic reticulum membraneMitochondrion membranePeroxisome membrane

VIAS BIOLÓGICAS (2)
Acyl chain remodelling of PCAcyl chain remodelling of PE
MECANISMO DE DOENÇA

Mitochondrial myopathy with lactic acidosis

An autosomal recessive disorder characterized by progressive muscle weakness, hypotonia, seizures, poor weight gain, lactic acidosis, and elevated serum pyruvate concentration. Some patients manifest growth failure and moderate neural deafness.

EXPRESSÃO TECIDUAL(Ubíquo)
Glândula adrenal
26.9 TPM
Brain Frontal Cortex BA9
24.5 TPM
Cérebro - Hemisfério cerebelar
22.4 TPM
Bladder
22.2 TPM
Artéria tibial
21.9 TPM
INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (1)
mitochondrial myopathy-lactic acidosis-deafness syndrome
HGNC:HGNC:28900UniProt:Q9NP80
COX15Heme A synthase COX15Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the second reaction in the biosynthesis of heme A, a prosthetic group of mitochondrial cytochrome c oxidase (CcO) (PubMed:12474143). Heme A is synthesized from heme B by two sequential enzymatic reactions catalyzed by heme O synthase (HOS) and heme A synthase (HAS). HAS catalyzes the conversion of heme O to heme A by two successive hydroxylations of the methyl group at C8, in a reaction that involves matrix ferredoxin and ferredoxin reductase. The first hydroxylation forms heme I, the

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (2)
Heme biosynthesisComplex IV assembly
MECANISMO DE DOENÇA

Mitochondrial complex IV deficiency, nuclear type 6

An autosomal recessive multisystem disorder with variable manifestations. Some patients present in the neonatal period with encephalomyopathic features, whereas others present later in the first year of life with developmental regression. Clinical features include microcephaly, encephalopathy, hypertrophic cardiomyopathy, persistent lactic acidosis, respiratory distress, hypotonia and seizures. Serum lactate is increased, and laboratory studies show decreased mitochondrial complex IV protein and activity levels.

OUTRAS DOENÇAS (2)
cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 2fatal infantile encephalocardiomyopathy
HGNC:2263UniProt:Q7KZN9
NDUFS4NADH dehydrogenase [ubiquinone] iron-sulfur protein 4, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (2)
Respiratory electron transportComplex I biogenesis
MECANISMO DE DOENÇA

Mitochondrial complex I deficiency, nuclear type 1

A form of mitochondrial complex I deficiency, the most common biochemical signature of mitochondrial disorders, a group of highly heterogeneous conditions characterized by defective oxidative phosphorylation, which collectively affects 1 in 5-10000 live births. Clinical disorders have variable severity, ranging from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
120.3 TPM
Artéria tibial
118.1 TPM
Fibroblastos
115.8 TPM
Ovário
114.4 TPM
Nervo tibial
104.8 TPM
OUTRAS DOENÇAS (2)
mitochondrial complex I deficiency, nuclear type 1mitochondrial complex I deficiency
HGNC:7711UniProt:O43181
LIG3DNA ligase 3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Isoform 3 functions as a heterodimer with DNA-repair protein XRCC1 in the nucleus and can correct defective DNA strand-break repair and sister chromatid exchange following treatment with ionizing radiation and alkylating agents. Isoform 1 is targeted to mitochondria, where it functions as a DNA ligase in mitochondrial base-excision DNA repair (PubMed:10207110, PubMed:24674627)

LOCALIZAÇÃO

MitochondrionNucleus

VIAS BIOLÓGICAS (5)
HDR through MMEJ (alt-NHEJ)Gap-filling DNA repair synthesis and ligation in TC-NERGap-filling DNA repair synthesis and ligation in GG-NERAPEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement PathwayResolution of AP sites via the single-nucleotide replacement pathway
MECANISMO DE DOENÇA

Mitochondrial DNA depletion syndrome 20, MNGIE type

An autosomal recessive mitochondrial disorder characterized by severe gut dysmotility, muscle weakness and atrophy, neurological abnormalities including epilepsy, migraine, stroke-like episodes, learning difficulties or cognitive decline, and neurogenic bladder. Brain imaging usually shows diffuse leukoencephalopathy and may show cerebellar atrophy. Disease onset can range from infancy to the teenage years.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
31.8 TPM
Útero
24.9 TPM
Fallopian Tube
22.8 TPM
Cervix Endocervix
18.8 TPM
Ovário
18.6 TPM
OUTRAS DOENÇAS (2)
mitochondrial DNA depletion syndrome 20 (mngie type)mitochondrial neurogastrointestinal encephalomyopathy
HGNC:6600UniProt:P49916
DNA2DNA replication ATP-dependent helicase/nuclease DNA2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Key enzyme involved in DNA replication and DNA repair in nucleus and mitochondrion. Involved in Okazaki fragments processing by cleaving long flaps that escape FEN1: flaps that are longer than 27 nucleotides are coated by replication protein A complex (RPA), leading to recruit DNA2 which cleaves the flap until it is too short to bind RPA and becomes a substrate for FEN1. Also involved in 5'-end resection of DNA during double-strand break (DSB) repair: recruited by BLM and mediates the cleavage o

LOCALIZAÇÃO

NucleusMitochondrion

VIAS BIOLÓGICAS (10)
Regulation of TP53 Activity through PhosphorylationG2/M DNA damage checkpointProcessing of DNA double-strand break endsPresynaptic phase of homologous DNA pairing and strand exchangeHDR through Single Strand Annealing (SSA)
MECANISMO DE DOENÇA

Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 6

A disorder characterized by muscle weakness, mainly affecting the lower limbs, external ophthalmoplegia, exercise intolerance, and mitochondrial DNA deletions on muscle biopsy. Symptoms may appear in childhood or adulthood and show slow progression.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
19.3 TPM
Cerebelo
6.4 TPM
Cérebro - Hemisfério cerebelar
6.3 TPM
Testículo
4.9 TPM
Pulmão
3.9 TPM
OUTRAS DOENÇAS (4)
mitochondrial DNA deletion syndrome with progressive myopathyRothmund-Thomson syndrome type 4Seckel syndrome 8Seckel syndrome
HGNC:2939UniProt:P51530
POLG2DNA polymerase subunit gamma-2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Accessory subunit of DNA polymerase gamma solely responsible for replication of mitochondrial DNA (mtDNA). Acts as an allosteric regulator of the holoenzyme activities. Enhances the polymerase activity and the processivity of POLG by increasing its interactions with the DNA template. Suppresses POLG exonucleolytic proofreading especially toward homopolymeric templates bearing mismatched termini. Binds to single-stranded DNA

LOCALIZAÇÃO

MitochondrionMitochondrion matrix, mitochondrion nucleoid

VIAS BIOLÓGICAS (2)
Strand-asynchronous mitochondrial DNA replicationTranscriptional activation of mitochondrial biogenesis
MECANISMO DE DOENÇA

Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 4

A disorder characterized by progressive weakness of ocular muscles and levator muscle of the upper eyelid. In a minority of cases, it is associated with skeletal myopathy, which predominantly involves axial or proximal muscles and which causes abnormal fatigability and even permanent muscle weakness. Ragged-red fibers and atrophy are found on muscle biopsy. A large proportion of chronic ophthalmoplegias are associated with other symptoms, leading to a multisystemic pattern of this disease. Additional symptoms are variable, and may include cataracts, hearing loss, sensory axonal neuropathy, ataxia, depression, hypogonadism, and parkinsonism.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
30.1 TPM
Ovário
22.2 TPM
Linfócitos
19.3 TPM
Cervix Endocervix
18.3 TPM
Útero
16.6 TPM
OUTRAS DOENÇAS (4)
progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 4mitochondrial DNA depletion syndrome 16 (hepatic type)mitochondrial dna depletion syndrome 16B (neuroophthalmic type)autosomal dominant progressive external ophthalmoplegia
HGNC:9180UniProt:Q9UHN1
TWNKTwinkle mtDNA helicaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Mitochondrial helicase involved in mtDNA replication and repair (PubMed:12975372, PubMed:15167897, PubMed:17324440, PubMed:18039713, PubMed:18971204, PubMed:25824949, PubMed:26887820, PubMed:27226550). Might have a role in mtDNA repair (PubMed:27226550). Has DNA strand separation activity needed to form a processive replication fork for leading strand synthesis which is catalyzed by the formation of a replisome complex with POLG and mtSDB (PubMed:12975372, PubMed:15167897, PubMed:18039713, PubMe

LOCALIZAÇÃO

Mitochondrion matrix, mitochondrion nucleoidMitochondrion inner membrane

VIAS BIOLÓGICAS (3)
Strand-asynchronous mitochondrial DNA replicationMitochondrial protein degradationTranscriptional activation of mitochondrial biogenesis
MECANISMO DE DOENÇA

Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 3

A disorder characterized by progressive weakness of ocular muscles and levator muscle of the upper eyelid. In a minority of cases, it is associated with skeletal myopathy, which predominantly involves axial or proximal muscles and which causes abnormal fatigability and even permanent muscle weakness. Ragged-red fibers and atrophy are found on muscle biopsy. A large proportion of chronic ophthalmoplegias are associated with other symptoms, leading to a multisystemic pattern of this disease. Additional symptoms are variable, and may include cataracts, hearing loss, sensory axonal neuropathy, ataxia, depression, hypogonadism, and parkinsonism.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
21.9 TPM
Testículo
20.3 TPM
Fibroblastos
14.6 TPM
Ovário
10.6 TPM
Útero
10.3 TPM
OUTRAS DOENÇAS (8)
mitochondrial DNA depletion syndrome 7 (hepatocerebral type)Perrault syndrome 5progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 3autosomal dominant progressive external ophthalmoplegia
HGNC:1160UniProt:Q96RR1
TOP3ADNA topoisomerase 3-alphaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Releases the supercoiling and torsional tension of DNA introduced during the DNA replication and transcription by transiently cleaving and rejoining one strand of the DNA duplex. Introduces a single-strand break via transesterification at a target site in duplex DNA. The scissile phosphodiester is attacked by the catalytic tyrosine of the enzyme, resulting in the formation of a DNA-(5'-phosphotyrosyl)-enzyme intermediate and the expulsion of a 3'-OH DNA strand. The free DNA strand then undergoes

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (10)
Regulation of TP53 Activity through PhosphorylationG2/M DNA damage checkpointProcessing of DNA double-strand break endsPresynaptic phase of homologous DNA pairing and strand exchangeHDR through Single Strand Annealing (SSA)
MECANISMO DE DOENÇA

Microcephaly, growth restriction, and increased sister chromatid exchange 2

An autosomal recessive disorder characterized by intrauterine growth restriction, poor postnatal growth with short stature and microcephaly, and increased sister chromatid exchange on cell studies.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
22.4 TPM
Testículo
20.8 TPM
Cérebro - Hemisfério cerebelar
18.7 TPM
Cerebelo
17.5 TPM
Fibroblastos
16.7 TPM
OUTRAS DOENÇAS (4)
progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 5microcephaly, growth restriction, and increased sister chromatid exchange 2intrauterine growth restriction-congenital multiple café-au-lait macules-increased sister chromatid exchange syndromeautosomal recessive progressive external ophthalmoplegia
HGNC:11992UniProt:Q13472
YARS2Tyrosine--tRNA ligase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the attachment of tyrosine to tRNA(Tyr) in a two-step reaction: tyrosine is first activated by ATP to form Tyr-AMP and then transferred to the acceptor end of tRNA(Tyr)

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (1)
Mitochondrial tRNA aminoacylation
MECANISMO DE DOENÇA

Myopathy with lactic acidosis and sideroblastic anemia 2

A rare oxidative phosphorylation disorder specific to skeletal muscle and bone marrow. Affected individuals manifest sideroblastic anemia, progressive lethargy, muscle weakness, and exercise intolerance associated with persistent lactic acidemia.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
29.8 TPM
Linfócitos
29.0 TPM
Cervix Endocervix
16.4 TPM
Útero
16.2 TPM
Cervix Ectocervix
16.1 TPM
OUTRAS DOENÇAS (2)
myopathy, lactic acidosis, and sideroblastic anemia 2myopathy, lactic acidosis, and sideroblastic anemia
HGNC:24249UniProt:Q9Y2Z4
PUS1Pseudouridylate synthase 1 homologDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Pseudouridylate synthase that catalyzes pseudouridylation of tRNAs and mRNAs (PubMed:15772074, PubMed:24722331). Acts on positions 27/28 in the anticodon stem and also positions 34 and 36 in the anticodon of an intron containing tRNA (PubMed:24722331). Also catalyzes pseudouridylation of mRNAs: mediates pseudouridylation of mRNAs with the consensus sequence 5'-UGUAG-3' (PubMed:31477916, PubMed:35051350). Acts as a regulator of pre-mRNA splicing by mediating pseudouridylation of pre-mRNAs at loca

LOCALIZAÇÃO

MitochondrionNucleusCytoplasm

VIAS BIOLÓGICAS (1)
tRNA modification in the nucleus and cytosol
MECANISMO DE DOENÇA

Myopathy with lactic acidosis and sideroblastic anemia 1

A rare oxidative phosphorylation disorder specific to skeletal muscle and bone marrow. Affected individuals manifest progressive muscle weakness, exercise intolerance, lactic acidosis, sideroblastic anemia and delayed growth.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
19.0 TPM
Fibroblastos
15.3 TPM
Baço
13.7 TPM
Testículo
13.4 TPM
Fallopian Tube
10.6 TPM
OUTRAS DOENÇAS (2)
myopathy, lactic acidosis, and sideroblastic anemia 1myopathy, lactic acidosis, and sideroblastic anemia
HGNC:15508UniProt:Q9Y606
TYMPThymidine phosphorylaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

May have a role in maintaining the integrity of the blood vessels. Has growth promoting activity on endothelial cells, angiogenic activity in vivo and chemotactic activity on endothelial cells in vitro Catalyzes the reversible phosphorolysis of thymidine. The produced molecules are then utilized as carbon and energy sources or in the rescue of pyrimidine bases for nucleotide synthesis

LOCALIZAÇÃO

VIAS BIOLÓGICAS (2)
Pyrimidine salvagePyrimidine catabolism
MECANISMO DE DOENÇA

Mitochondrial DNA depletion syndrome 1, MNGIE type

A multisystem disease associated with mitochondrial dysfunction. It is clinically characterized by onset between the second and fifth decades of life, ptosis, progressive external ophthalmoplegia, gastrointestinal dysmotility (often pseudoobstruction), diffuse leukoencephalopathy, cachexia, peripheral neuropathy, and myopathy.

EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
330.6 TPM
Pulmão
260.6 TPM
Baço
215.3 TPM
Tecido adiposo
140.0 TPM
Adipose Visceral Omentum
116.4 TPM
OUTRAS DOENÇAS (2)
mitochondrial DNA depletion syndrome 1mitochondrial neurogastrointestinal encephalomyopathy
HGNC:3148UniProt:P19971
HADHBTrifunctional enzyme subunit beta, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Mitochondrial trifunctional enzyme catalyzes the last three of the four reactions of the mitochondrial beta-oxidation pathway (PubMed:29915090, PubMed:30850536, PubMed:8135828). The mitochondrial beta-oxidation pathway is the major energy-producing process in tissues and is performed through four consecutive reactions breaking down fatty acids into acetyl-CoA (PubMed:29915090). Among the enzymes involved in this pathway, the trifunctional enzyme exhibits specificity for long-chain fatty acids (P

LOCALIZAÇÃO

MitochondrionMitochondrion inner membraneMitochondrion outer membraneEndoplasmic reticulum

VIAS BIOLÓGICAS (8)
Acyl chain remodeling of CLBeta oxidation of hexanoyl-CoA to butanoyl-CoABeta oxidation of octanoyl-CoA to hexanoyl-CoABeta oxidation of decanoyl-CoA to octanoyl-CoA-CoABeta oxidation of lauroyl-CoA to decanoyl-CoA-CoA
MECANISMO DE DOENÇA

Mitochondrial trifunctional protein deficiency 2

An autosomal recessive metabolic disorder of long-chain fatty acid oxidation, biochemically characterized by loss of all enzyme activities of the mitochondrial trifunctional protein complex. The disease phenotype ranges from a fatal form characterized by early-onset cardiomyopathy, cardiac failure and early death to less severe, late-onset forms with myopathy, recurrent rhabdomyolysis, and sensorimotor axonal neuropathy as key features.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
375.3 TPM
Coração - Ventrículo esquerdo
307.5 TPM
Coração - Átrio
223.3 TPM
Glândula adrenal
186.5 TPM
Esôfago - Muscular
129.0 TPM
OUTRAS DOENÇAS (2)
mitochondrial trifunctional protein deficiency 2mitochondrial trifunctional protein deficiency
HGNC:4803UniProt:P55084
POLGDNA polymerase subunit gamma-1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalytic subunit of DNA polymerase gamma solely responsible for replication of mitochondrial DNA (mtDNA). Replicates both heavy and light strands of the circular mtDNA genome using a single-stranded DNA template, RNA primers and the four deoxyribonucleoside triphosphates as substrates (PubMed:11477093, PubMed:11897778, PubMed:15917273, PubMed:19837034, PubMed:9558343). Has 5' -> 3' polymerase activity. Functionally interacts with TWNK and SSBP1 at the replication fork to form a highly processiv

LOCALIZAÇÃO

MitochondrionMitochondrion matrix, mitochondrion nucleoid

VIAS BIOLÓGICAS (1)
Strand-asynchronous mitochondrial DNA replication
MECANISMO DE DOENÇA

Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 1

A disorder characterized by progressive weakness of ocular muscles and levator muscle of the upper eyelid. In a minority of cases, it is associated with skeletal myopathy, which predominantly involves axial or proximal muscles and which causes abnormal fatigability and even permanent muscle weakness. Ragged-red fibers and atrophy are found on muscle biopsy. A large proportion of chronic ophthalmoplegias are associated with other symptoms, leading to a multisystemic pattern of this disease. Additional symptoms are variable, and may include cataracts, hearing loss, sensory axonal neuropathy, ataxia, depression, hypogonadism, and parkinsonism.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
48.3 TPM
Linfócitos
42.0 TPM
Baço
41.5 TPM
Útero
40.9 TPM
Pulmão
38.7 TPM
OUTRAS DOENÇAS (11)
sensory ataxic neuropathy, dysarthria, and ophthalmoparesismitochondrial DNA depletion syndrome 4bmitochondrial DNA depletion syndrome 4amitochondrial disease
HGNC:9179UniProt:P54098
SCO2Cytochrome c oxidase assembly factor SCO2Disease-causing germline mutation(s) inDesconhecido
FUNÇÃO

Copper metallochaperone essential for the synthesis and maturation of cytochrome c oxidase subunit II (MT-CO2/COX2); together with SCO1, facilitates the incorporation of copper into the Cu(A) site of MT-CO2/COX2 (PubMed:15229189, PubMed:17189203, PubMed:19336478, PubMed:35750769). Could also act as a thiol-disulfide oxidoreductase to regulate the redox state of the cysteines in SCO1 during maturation of MT-CO2/COX2 (PubMed:19336478)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (2)
TP53 Regulates Metabolic GenesComplex IV assembly
MECANISMO DE DOENÇA

Mitochondrial complex IV deficiency, nuclear type 2

An autosomal recessive, severe mitochondrial disorder characterized by hypotonia, global developmental delay, hypertrophic cardiomyopathy, lactic acidosis, gliosis, and neuronal loss in basal ganglia, brainstem and spinal cord. Serum lactate is increased, and laboratory studies show decreased mitochondrial complex IV protein and activity levels in various tissues, including heart and skeletal muscle. Most patients die in infancy of cardiorespiratory failure.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
32.4 TPM
Pulmão
32.3 TPM
Fibroblastos
29.5 TPM
Esôfago - Mucosa
28.2 TPM
Fallopian Tube
28.1 TPM
OUTRAS DOENÇAS (5)
cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 1myopia 6autosomal recessive axonal charcot-marie-tooth disease due to copper metabolism defectfatal infantile encephalocardiomyopathy
HGNC:10604UniProt:O43819
COA6Cytochrome c oxidase assembly factor 6 homologDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Involved in the maturation of the mitochondrial respiratory chain complex IV subunit MT-CO2/COX2. Thereby, may regulate early steps of complex IV assembly. Mitochondrial respiratory chain complex IV or cytochrome c oxidase is the component of the respiratory chain that catalyzes the transfer of electrons from intermembrane space cytochrome c to molecular oxygen in the matrix and as a consequence contributes to the proton gradient involved in mitochondrial ATP synthesis. May also be required for

LOCALIZAÇÃO

Mitochondrion intermembrane space

VIAS BIOLÓGICAS (1)
Mitochondrial protein import
MECANISMO DE DOENÇA

Mitochondrial complex IV deficiency, nuclear type 13

An autosomal recessive, infantile disorder with a fatal course in the first weeks of life, characterized by hypertrophic cardiomyopathy, left ventricular non-compaction, lactic acidosis, metabolic hypotonia, and mitochondrial complex IV deficiency.

OUTRAS DOENÇAS (2)
cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 4fatal infantile encephalocardiomyopathy
HGNC:18025UniProt:Q5JTJ3

Variantes genéticas (ClinVar)

765 variantes patogênicas registradas no ClinVar.

🧬 SDHA: GRCh38/hg38 5p15.33-15.32(chr5:113462-5578808)x1 ()
🧬 SDHA: NM_004168.4(SDHA):c.1517dup (p.Arg507fs) ()
🧬 SDHA: NM_004168.4(SDHA):c.896-1G>A ()
🧬 SDHA: NM_004168.4(SDHA):c.1648A>T (p.Lys550Ter) ()
🧬 SDHA: NM_004168.4(SDHA):c.567C>A (p.Cys189Ter) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 333 variantes classificadas pelo ClinVar.

35
193
105
Patogênica (10.5%)
VUS (58.0%)
Benigna (31.5%)
VARIANTES MAIS SIGNIFICATIVAS
MSTO1: NM_018116.4(MSTO1):c.595del (p.Glu199fs) [Pathogenic]
PNPLA8: NM_001256007.3(PNPLA8):c.620dup (p.Leu207fs) [Pathogenic]
CHCHD10: NM_213720.3(CHCHD10):c.287C>T (p.Pro96Leu) [Uncertain significance]
CHCHD10: NM_213720.3(CHCHD10):c.206T>G (p.Leu69Arg) [Uncertain significance]
CHCHD10: NM_213720.3(CHCHD10):c.41+3G>A [Uncertain significance]

Vias biológicas (Reactome)

116 vias biológicas associadas aos genes desta condição.

Respiratory electron transport Citric acid cycle (TCA cycle) Maturation of TCA enzymes and regulation of TCA cycle Complex IV assembly Formation of ATP by chemiosmotic coupling Mitochondrial translation termination Cristae formation Signaling by NOTCH4 Regulation of CDH1 Gene Transcription Negative Regulation of CDH1 Gene Transcription TP53 Regulates Metabolic Genes NOTCH4 Activation and Transmission of Signal to the Nucleus Signaling by WNT Signaling by NOTCH2 rRNA modification in the nucleus and cytosol PTEN Regulation Regulation of PTEN gene transcription Cytoprotection by HMOX1 Mitochondrial protein degradation WNT mediated activation of DVL ABC transporter disorders Defective ABCA3 causes SMDP3 Strand-asynchronous mitochondrial DNA replication Regulation of CDH11 Expression and Function Regulation of CDH11 gene transcription Intracellular oxygen transport Mitochondrial unfolded protein response (UPRmt) NADE modulates death signalling Activation of BIM and translocation to mitochondria Complex I biogenesis Activation of caspases through apoptosome-mediated cleavage Ubiquinol biosynthesis Export of Viral Ribonucleoproteins from Nucleus NEP/NS2 Interacts with the Cellular Export Machinery Regulation of CDH1 mRNA translation by microRNAs Regulation of RUNX1 Expression and Activity Sensing of DNA Double Strand Breaks Processing of DNA double-strand break ends HDR through MMEJ (alt-NHEJ) Nonhomologous End-Joining (NHEJ) DNA Damage/Telomere Stress Induced Senescence tRNA modification in the mitochondrion Signaling by MET Signaling by ERBB2 KD Mutants Sensory perception of sweet, bitter, and umami (glutamate) taste NOTCH3 Intracellular Domain Regulates Transcription Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 Activation of C3 and C5 cRNA Synthesis Transcriptional regulation by RUNX3 TP53 Regulates Transcription of Caspase Activators and Caspases TP53 Regulates Transcription of Cell Death Genes Defective homologous recombination repair (HRR) due to PALB2 loss of function Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function NPAS4 regulates expression of target genes Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Neutrophil degranulation Purine salvage Transcriptional regulation by RUNX2 NOTCH2 Activation and Transmission of Signal to the Nucleus Response of endothelial cells to shear stress Developmental Cell Lineages SARS-CoV-2 Infection Downregulation of ERBB2 signaling Regulation of CDH1 Expression and Function Regulation of RUNX2 expression and activity Defective MUTYH substrate processing Defective Base Excision Repair Associated with NEIL1 Virion Assembly and Release Virion Assembly and Release IKK complex recruitment mediated by RIP1 Transcriptional regulation by RUNX1 Acyl chain remodeling of CL Beta oxidation of myristoyl-CoA to lauroyl-CoA mitochondrial fatty acid beta-oxidation of unsaturated fatty acids Beta oxidation of palmitoyl-CoA to myristoyl-CoA Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA Beta oxidation of octanoyl-CoA to hexanoyl-CoA Beta oxidation of hexanoyl-CoA to butanoyl-CoA Mitochondrial iron-sulfur cluster biogenesis Pregnenolone biosynthesis Endogenous sterols Electron transport from NADPH to Ferredoxin Defective CYP11A1 causes AICSR Mitochondrial protein import Pyrimidine salvage Mitochondrial Uncoupling Vpr-mediated induction of apoptosis by mitochondrial outer membrane permeabilization Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane Interconversion of nucleotide di- and triphosphates Acyl chain remodelling of PC Acyl chain remodelling of PE Heme biosynthesis Resolution of AP sites via the single-nucleotide replacement pathway APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway Gap-filling DNA repair synthesis and ligation in GG-NER Gap-filling DNA repair synthesis and ligation in TC-NER Removal of the Flap Intermediate from the C-strand HDR through Single Strand Annealing (SSA) HDR through Homologous Recombination (HRR) Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) Resolution of D-loop Structures through Holliday Junction Intermediates Homologous DNA Pairing and Strand Exchange Presynaptic phase of homologous DNA pairing and strand exchange Regulation of TP53 Activity through Phosphorylation Removal of the Flap Intermediate G2/M DNA damage checkpoint Defective homologous recombination repair (HRR) due to BRCA1 loss of function Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function Impaired BRCA2 binding to RAD51 Impaired BRCA2 binding to PALB2 Transcriptional activation of mitochondrial biogenesis Meiotic recombination Mitochondrial tRNA aminoacylation tRNA modification in the nucleus and cytosol

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 32
2Fase 26
·Pré-clínico3
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 11 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Miopatia mitocondrial

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

5 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

90 ensaios clínicos encontrados, 6 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
611 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 611

#1

Statins in Genetic Myopathies: A Retrospective Analysis of Safety and Tolerability.

Neurology. Clinical practice2026 Feb

Statins are widely prescribed lipid-lowering agents, but their safety and tolerability in patients with underlying genetic myopathies remain uncertain. We aimed to study statin safety and tolerability in genetic myopathies using a large retrospective cohort. We conducted a retrospective study in patients with myotonic dystrophy type 1 (DM1) and type 2 (DM2), facioscapulohumeral dystrophy (FSHD), limb-girdle muscular dystrophy (LGMD), and metabolic or mitochondrial myopathies who were exposed to statins. We included 135 patients (36 with DM1, 46 with DM2, 22 with FSHD, 6 with LGMD, 17 with mitochondrial myopathy, 6 with glycogenosis, and 2 with disorders of fatty acid oxidation or carnitine transport). A total of 44 patients discontinued statins, most often for statin-associated muscle symptoms (SAMS; n = 20). SAMS occurred in 36 of 135 patients (26.67%; 8 with DM1, 10 with DM2, 7 with FSHD, 3 with LGMD, 4 with mitochondrial myopathy, and 4 with metabolic myopathy). Myalgias were the most frequent SAMS (n = 29). Rhabdomyolysis occurred in 4 patients (1 with mitochondrial myopathy and 3 with McArdle disease). Statins unmasked myopathy in 6 of 36 patients. No patient developed immune-mediated necrotizing myopathy. SAMS are generally mild and occur at a frequency similar to the general population in common genetic myopathies, except increased rhabdomyolysis in mitochondrial myopathies and McArdle disease. Statins are generally safe, though not well tolerated, and could be used when closely monitored in several genetic myopathies. In mitochondrial and metabolic myopathies, their use should be approached with caution because of the potential risk of rhabdomyolysis.

#2

Fusion Between Control Mesoangioblasts and mtDNA-Mutant Myotubes Preserves Myotube Morphology and Mitochondrial Network Organization.

International journal of molecular sciences2026 Jan 29

Mitochondria are the energy factories of a cell and mitochondrial morphology, quantity, membrane potential, and DNA copy number can change depending on metabolic requirements and/or genetic defects. Different mutations in mitochondrial DNA might affect mitochondrial morphology and membrane potential differently. In this study we investigated mitochondrial morphology and membrane potential in vitro in mesoangioblast-derived human myotubes harboring a pathogenic mtDNA mutation and analyzed mitochondrial behavior following fusion with healthy mesoangioblasts. Myotubes were differentiated in vitro from mesoangioblasts obtained from two mitochondrial myopathy patients, M02 (96% m.3271T>C) and M11 (73% m.3291T>C), and from a functionally healthy male control, M06 (3% m.3243A>G). On day 5 of differentiation, healthy male mesoangioblasts (mM06) were added to mutant myotube cultures to allow cell fusion. On day 11, mitochondrial morphology and membrane potential were assessed by three-dimensional live-cell imaging using spinning disk confocal microscopy with tetramethylrhodamine methyl ester (TMRM). Following live imaging, cells were fixed and subjected to Y-chromosome fluorescence in situ hybridization (FISH), enabling identification and retrospective analysis of hybrid (i.e., fused with male control mesoangioblasts) and non-hybrid (i.e., not fused with these control mesoangioblasts) myotubes within the same imaging fields. Quantitative image analysis at the level of individual myotubes revealed that, when normalized to sarcoplasmic volume, mitochondrial volume, object number, and membrane potential did not differ between mutant and control myotubes despite heteroplasmy levels exceeding 70%. Fusion of healthy mM06 mesoangioblasts did not impair myotube formation and resulted in redistribution of mitochondrial content without an increase in mitochondrial object number, consistent with integration of donor mitochondria into the existing mitochondrial network. Across conditions, mitochondrial parameters were strongly influenced by myotube size, underscoring the importance of accounting for biological variation when quantifying mitochondrial features. Together, these findings demonstrate that high mtDNA mutation loads do not necessarily alter mitochondrial morphology or membrane potential under standard in vitro differentiation conditions and provide mechanistic insight into mitochondrial behavior following mesoangioblast fusion in human myotubes. Fusion of healthy mesoangioblasts supports integration of donor mitochondria into the existing network without compromising myogenesis, consistent with mitochondrial mixing rather than replacement.

#3

Loss of Myofilaments in Gastrointestinal Smooth Muscle: A Novel Pathological Finding in MELAS-Associated Chronic Intestinal Pseudo-Obstruction.

Neurogastroenterology and motility2026 Feb

Chronic intestinal pseudo-obstruction (CIPO) occurs in up to 40% of patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS). While enteric nervous system abnormalities have been documented, 15%-38% of CIPO cases show normal histology, suggesting alternative pathogenic mechanisms. We aimed to investigate smooth muscle pathology in MELAS-associated CIPO. Comprehensive pathological examination including light and electron microscopy was performed on autopsy material from a 52-year-old male with MELAS (m.3243A > G mutation) and recurrent intestinal obstruction symptoms. Gastrointestinal tissue from the entire digestive tract was analyzed and compared with age-matched control tissue. Histological examination revealed widespread vacuolization and pallor of gastrointestinal smooth muscle throughout the digestive tract (esophagus, stomach, duodenum, and colon). Electron microscopy demonstrated abundant abnormal mitochondria in smooth muscle cells and, notably, marked loss of myofilaments in the colonic muscle. The ultrastructural preservation was limited by postmortem changes (autolysis, occurring approximately 4 h after death) and the re-embedding technique from formalin-fixed paraffin-embedded tissue; however, the striking difference was evident compared to age-matched controls. Similar abnormalities were observed in the Auerbach plexus. This represents the first report of myofilament loss in MELAS-associated CIPO, suggesting that mitochondrial dysfunction may directly impair smooth muscle contractile apparatus beyond previously described neuronal abnormalities. These findings provide novel insights into CIPO pathogenesis and may inform therapeutic strategies emphasizing early enteral nutrition interventions that bypass affected gastrointestinal segments.

#4

A Case of Mitochondrial Myopathy, Lactic Acidosis and Sideroblastic Anemia (MLASA Syndrome) and Long QT Interval in a 10-Year-Old Saudi Child.

Saudi journal of medicine & medical sciences2026

MLASA syndrome is a rare mitochondrial disorder that presents in three distinct genetic forms: MLASA1, MLASA2, and MLASA3; MLASA1 is the most common form. The clinical features include mitochondrial myopathy, lactic acidosis, and sideroblastic anemia. Although presence of other features is not uncommon, its association with long QT (LQT) syndrome has not been described before. In addition, while MLASA syndrome has been reported from several countries worldwide, we present the first patient with MLASA1 syndrome from the Kingdom of Saudi Arabia in this case report. The 10-year-old girl with history of poor health since infancy and recurrent hospital admissions for infections and blood transfusions was referred to our hospital for allogeneic bone marrow transplantation. Early in her childhood, she was diagnosed with symptomatic LQT syndrome and, at a later age, with sideroblastic anemia. Whole-exome sequencing (WES) revealed homozygous mutations in the PUS1 gene and heterozygous mutations in the KCNQ1 gene. The WES test of the parents was negative, and there was no family history suggestive of a similar diagnosis. Therefore, our patient has most probably developed the syndrome as a result of a sporadic de novo mutation; however, the possibility of sex cell germline mosaicism cannot be excluded. Heterozygous KCNQ1 gene mutation is associated with the development of type 1 LQT syndrome. Detection of the MLASA syndrome and proper intervention at an early age are crucial for successful management. Associated LQT syndrome should always be anticipated. Despite the presence of a fully tissue-matched sibling, the parents of our patient declined the option of allogeneic bone marrow transplantation due to potential severe cardiac and liver complications.

#5

Exploring Outcome Measures for Mitochondrial Myopathies; Insights From a Longitudinal Study on TK2 Deficiency.

Journal of inherited metabolic disease2026 Jan

Thymidine kinase 2 deficiency (TK2d) is an ultra-rare autosomal recessive mitochondrial myopathy with variable presentations, including late-onset forms beginning after age 12. Unlike early-onset disease, the natural history of late-onset TK2d remains poorly defined. We conducted a prospective, single-centre natural history study of 11 untreated patients with late-onset TK2d over 24 months. The median age at symptom onset was 27.2 years. Clinical phenotypes included progressive myopathy (n = 7), chronic progressive external ophthalmoplegia plus (n = 2), and exercise intolerance (n = 2). Most patients (72%) required non-invasive ventilation, and 70% showed axonal polyneuropathy. All patients carried biallelic pathogenic TK2 variants, with p.Lys202del being the most common (13/22 alleles). Muscle biopsies demonstrated mitochondrial DNA depletion and multiple deletions, and muscle MRI consistently showed selective involvement of the sartorius, gracilis and gluteus maximus, whose fat fraction correlated with motor impairment. Functional assessments revealed a mean forced vital capacity of 70.4%, an NSAA score of 25.9, a six-minute walk distance of 479.5 m, and a 100-m run time of 60.5 s. Serum GDF15 levels were elevated (median 2747.5 pg/mL) and significantly correlated with motor and respiratory function. Over 2 years, patients showed measurable clinical deterioration, with declines in NSAA (-2.65 points), FVC (-9.11%), and worsening 100-meter run times (+6 s). This study provides the first prospective longitudinal characterization of late-onset TK2d and identifies clinically relevant, quantifiable outcomes that may inform future therapeutic trials targeting this underrepresented patient population. Moreover, these results are also relevant for the design of clinical trials in other mitochondrial myopathies.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC827 artigos no totalmostrando 197

2026

Anaesthethic management on a pediatric patient with Sengers syndrome. Case report.

Revista espanola de anestesiologia y reanimacion
2026

Late-onset TK2 deficiency in adults: Long-term clinical outcomes of deoxynucleoside therapy.

Mitochondrion
2026

Progressive Myopathy and Respiratory Failure in a 7-Year-Old Boy With m.3251A>G MT-TL1 Mutation.

Journal of clinical neuromuscular disease
2026

Effects of Cacao Flavonoids in Long COVID-19 Patients with Chronic Fatigue: FLALOC, a Placebo-Controlled Randomized Clinical Trial.

Journal of clinical medicine
2026

Statins in Genetic Myopathies: A Retrospective Analysis of Safety and Tolerability.

Neurology. Clinical practice
2026

Fusion Between Control Mesoangioblasts and mtDNA-Mutant Myotubes Preserves Myotube Morphology and Mitochondrial Network Organization.

International journal of molecular sciences
2026

Loss of Myofilaments in Gastrointestinal Smooth Muscle: A Novel Pathological Finding in MELAS-Associated Chronic Intestinal Pseudo-Obstruction.

Neurogastroenterology and motility
2026

Rhabdomyolysis due to mtDNA pathogenic variants: Report of a subject with a novel MT-CO3 variant and review of the literature.

Molecular genetics and metabolism
2026

A Case of Mitochondrial Myopathy, Lactic Acidosis and Sideroblastic Anemia (MLASA Syndrome) and Long QT Interval in a 10-Year-Old Saudi Child.

Saudi journal of medicine & medical sciences
2026

MSTO1-related mitochondrial myopathy and ataxia syndrome: Case series and literature review.

Neuromuscular disorders : NMD
2026

Invasive cardiopulmonary exercise testing: Physiologic assessment of unexplained dyspnea and exercise intolerance.

Respiratory physiology & neurobiology
2026

Taurine intake ameliorates lactic acidosis and hyperferritinemia occurring after mRNA SARS-CoV-2 vaccination in a patient with β-thalassemia trait: a case report and review of literature.

Journal of medical case reports
2026

Mitochondrial Myopathy, Lactic Acidosis, and Stroke-Like Episodes Combined with Diabetes: A Case Report.

Endocrine, metabolic & immune disorders drug targets
2026

Exploring Outcome Measures for Mitochondrial Myopathies; Insights From a Longitudinal Study on TK2 Deficiency.

Journal of inherited metabolic disease
2026

Clinical and Genotypic Spectrum of Twinkle-Related Disorders: Insights From a Multinational Cohort Study.

Neurology
2025

Diagnostic Value of Muscle Biopsy for the Evaluation of Adult Myopathy in Daily Clinical Practice.

Diagnostics (Basel, Switzerland)
2025

Transient muscle expression of mitoARCUS in mice leads to sustained reductions in pathogenic mtDNA and reduces fatigability.

Molecular therapy : the journal of the American Society of Gene Therapy
2025

A Novel Variant in the TAMM41-Associated Mitochondrial Myopathy.

American journal of medical genetics. Part A
2025

A novel mutation in FDX2 provides insights into the pathogenesis of MEOAL mitochondrial neuromuscular disease.

Cell death & disease
2025

Clinical insights into mitochondrial retinopathy: A case report on m.3243A>G mutation and macular dystrophy.

Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society
2025

Copper deficiency disrupts OXPHOS and mitochondrial dynamics through MTCH2-dependent copper trafficking in skeletal muscle.

bioRxiv : the preprint server for biology
2025

Cardiac magnetic resonance findings in mitochondrial disease: a guide for clinicians.

European heart journal. Imaging methods and practice
2025

Mitochondrial cardiomyopathy with skeletal muscle myopathy caused by m.3260A > G mutation in MT-TL1 gene: a case report.

Journal of medical case reports
2025

Diagnosis of MG and differential diagnoses.

International review of neurobiology
2025

Systemic lipomatosis as a clue to mitochondrial myopathy.

Practical neurology
2026

Expanding the Clinical Spectrum of Mitochondrial Phosphate Carrier Deficiency: A Case Report With Literature Review.

American journal of medical genetics. Part A
2025

Nucleos(t)ide Therapy for TK2-Deficient Mitochondrial Myopathy: Small Molecules With Big Potential.

Neurology
2025

Pyrimidine Nucleos(t)ide Therapy in Patients With Thymidine Kinase 2 Deficiency: A Multicenter Retrospective Chart Review Study.

Neurology
2025

NAD+ dyshomeostasis in RYR1-related myopathies.

Skeletal muscle
2025

What Is the Potential Relevance of Growth and Differentiation Factor-15 in Neurologic Disease?

Neurology
2025

McLeod syndrome mimicking mitochondrial myopathy due to a novel in-frame duplication in the XK gene.

Neuromuscular disorders : NMD
2025

Elamipretide in the Management of Barth Syndrome: Current Evidence and a Case Report.

Molecular genetics and metabolism
2025

Congenital-onset MLASA2 from a novel YARS2 variant: A literature review.

Journal of neuromuscular diseases
2025

Systemic mitochondrial involvement in mitochondrial myopathy with episodic hyper-creatine kinase-emia: insights from an autopsy case.

Journal of neurology
2026

RePOWER: An International, Prospective, Non-Interventional Registry of Patients With Primary Mitochondrial Myopathy.

Clinical genetics
2025

Updates on Mitochondrial Myopathies.

Current neurology and neuroscience reports
2025

The profound implications of mitochondrial myopathy on activities of daily living: an observational qualitative study of standardized structured and semi-structured patient interviews.

Therapeutic advances in chronic disease
2025

Dual diagnosis of neurobrucellosis and Anti-LGI1 encephalitis: a rare case report.

BMC infectious diseases
2025

Intra-arterial transplantation of autologous mesoangioblasts in m.3243A>G mutation carriers is safe: First phase 1/2 human clinical study.

Molecular therapy : the journal of the American Society of Gene Therapy
2025

PDK4 and nutrient responses explain muscle specific manifestation in mitochondrial disease.

Clinical and translational medicine
2025

Anesthetic Management With Remimazolam for Adolescent Mitochondrial Encephalomyopathy With Lactic Acidosis and Stroke-like Episodes (MELAS): A Case Report.

Anesthesia progress
2025

Clinical and Pathological Features of Flexural Deformities Associated with Myopathies in Foals.

Veterinary sciences
2025

Postoperative outcomes in mitochondrial myopathy-associated ptosis: a case series.

International ophthalmology
2025

OXA1L deficiency causes mitochondrial myopathy via reactive oxygen species regulated nuclear factor kappa B signalling pathway.

Clinical and translational medicine
2025

Seventeen-year follow-up of mitochondrial myopathy and ataxia in a Chinese family: case reports and literature review.

Documenta ophthalmologica. Advances in ophthalmology
2025

Autosomal dominant myopathy caused by a novel ISCU variant.

Frontiers in genetics
2025

Tissue-specific mitochondrial DNA, MT-TF, pathogenic variants in mitochondrial myopathies.

Molecular genetics and metabolism reports
2025

A Clinical Study on the Utility of Muscle Biopsy in Patients with Suspected Myopathy.

Annals of Indian Academy of Neurology
2025

Mitochondrial myopathy revealed postoperative acute respiratory failure: A case report.

World journal of clinical cases
2025

Emerging atypical clinicopathological manifestations of immune-mediated necrotizing myopathy (IMNM).

Neuromuscular disorders : NMD
2025

Contemporary insights into elamipretide's mitochondrial mechanism of action and therapeutic effects.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
2025

280th ENMC International Workshop: The ERN EURO-NMD mitochondrial diseases working group; diagnostic criteria and outcome measures in primary mitochondrial myopathies. Hoofddorp, the Netherlands, 22-24 November 2024.

Neuromuscular disorders : NMD
2025

Interpreting the clinical significance of multiple large-scale mitochondrial DNA deletions (MLSMD) in skeletal muscle tissue in the diagnostic evaluation of primary mitochondrial disease.

Frontiers in pharmacology
2025

Measurement of Twitch Dynamics in Response to Exercise Induced Changes in Mitochondrial Disease Using Motor Unit Magnetic Resonance Imaging (MUMRI): A Proof-of-Concept Study.

NMR in biomedicine
2025

Novel cytochrome c-oxidase deficiency and mitochondrial myopathy in non-syndromic cleft lip with or without palate.

Tissue & cell
2025

Diagnosis of Primary Mitochondrial Diseases.

Muscle & nerve
2025

Clinical and molecular spectrum of TK2-deficiency: a large Brazilian cohort.

Scientific reports
2025

PHEMI-Phenylbutyrate in Patients With Lactic Acidosis: A Pilot, Single Arm, Phase I/II, Open-Label Trial.

Clinical therapeutics
2025

A lipid droplet-targeted probe for imaging of lipid metabolism disorders during mitochondrial myopathy.

Talanta
2025

Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) with high-frequency oscillations on scalp EEG: A case report.

Epilepsy & behavior reports
2025

A Case of Infantile Reversible Cytochrome C Oxidase Deficiency Myopathy in Taiwan: A 4-Year Follow-Up.

Case reports in medicine
2025

GDF15 Neutralization Ameliorates Muscle Atrophy and Exercise Intolerance in a Mouse Model of Mitochondrial Myopathy.

Journal of cachexia, sarcopenia and muscle
2025

Endurance swimming exacerbates mitochondrial myopathy in mice with high mtDNA deletions.

Mitochondrion
2025

Cardiac manifestations in adult MELAS syndrome (mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes syndrome)- a cross-sectional study.

Orphanet journal of rare diseases
2025

A window into intracellular events in myositis through subcellular proteomics.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]
2025

Comprehensive analysis of GDF15 as a biomarker in primary mitochondrial myopathies.

Molecular genetics and metabolism
2025

Genotype-Phenotype Correlation in Progressive External Ophthalmoplegia: Insights From a Retrospective Analysis.

Neuropathology and applied neurobiology
2025

Unraveling the genetic spectrum of inherited deaf-blindness in Portugal.

Orphanet journal of rare diseases
2025

Ptosis in human immunodeficiency virus-infected patients under long-term antiretroviral treatment.

Clinical neurology and neurosurgery
2025

Cyclosporine A Delays the Terminal Disease Stage in the Tfam KO Mitochondrial Myopathy Mouse Model Without Improving Mitochondrial Energy Production.

Muscle & nerve
2024

Ketogenic diet in adult patients with mitochondrial myopathy.

Molecular genetics and metabolism
2024

Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.

Orphanet journal of rare diseases
2024

Post-sepsis chronic muscle weakness can be prevented by pharmacological protection of mitochondria.

Molecular medicine (Cambridge, Mass.)
2024

Very-late-onset multiple Acyl-coenzyme a dehydrogenase deficiency with elevated GDF-15 and Aldolase: a case report.

Neuromuscular disorders : NMD
2024

Sucla2 Knock-Out in Skeletal Muscle Yields Mouse Model of Mitochondrial Myopathy With Muscle Type-Specific Phenotypes.

Journal of cachexia, sarcopenia and muscle
2024

Unraveling the molecular determinants of a rare human mitochondrial disorder caused by the P144L mutation of FDX2.

Protein science : a publication of the Protein Society
2025

MELAS Presenting as Bilateral Symmetric Occipital and Temporal Cortices Lesions: A Case Report and Literature Review.

The neurologist
2024

Targeted nanopore sequencing using the Flongle device to identify mitochondrial DNA variants.

Scientific reports
2024

Post-transcriptional methylation of mitochondrial-tRNA differentially contributes to mitochondrial pathology.

Nature communications
2024

Moyamoya syndrome secondary to MELAS syndrome in a child: A case report and literature revue.

Radiology case reports
2024

DELE1 maintains muscle proteostasis to promote growth and survival in mitochondrial myopathy.

The EMBO journal
2024

[Taurine for Mitochondrial Diseases].

Brain and nerve = Shinkei kenkyu no shinpo
2024

Prenatal and progressive coenzyme Q10 administration to mitigate muscle dysfunction in mitochondrial disease.

Journal of cachexia, sarcopenia and muscle
2024

New Insights into Mitochondria in Health and Diseases.

International journal of molecular sciences
2025

Wolff-Parkinson-White Syndrome in a Patient with Mitochondrial Myopathy.

Clinical pediatrics
2024

Severe Respiratory and Swallowing Disorders in Infantile-Onset Multisystem Neurologic, Endocrine, and Pancreatic Disease Type 1: Two Cases.

Neurology. Genetics
2024

Niacin supplementation in a child with novel MTTN variant m.5670A>G causing early onset mitochondrial myopathy and NAD+ deficiency.

Neuromuscular disorders : NMD
2024

NAD+ precursors prolong survival and improve cardiac phenotypes in a mouse model of Friedreich's Ataxia.

JCI insight
2024

Multi-Allelic Mitochondrial DNA Deletions in an Adult Dog with Chronic Weakness, Exercise Intolerance and Lactic Acidemia.

Animals : an open access journal from MDPI
2024

Vitamin B12 Deficiency-Induced Neuropathy and Cognitive and Motor Impairment in the Elderly: A Case Study.

Food and nutrition bulletin
2024

Multiomics analysis reveals serine catabolism as a potential therapeutic target for MELAS.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
2024

Unsuspected Mitochondrial Myopathy Unveiled by Invasive Cardiopulmonary Exercise Testing.

Circulation. Heart failure
2024

Leber's hereditary optic neuropathy like disease in MT-ATP6 variant m.8969G>A.

American journal of ophthalmology case reports
2024

Point-of-Care Ultrasound for the Diagnosis of Congestive Kidney Due to Severe Acidemia: A Case Report.

Cureus
2024

Mitochondrial tRNA pseudouridylation governs erythropoiesis.

Blood
2024

Arginine Supplementation in MELAS Syndrome: What Do We Know about the Mechanisms?

International journal of molecular sciences
2024

Remarkable clinical improvement with oral nucleoside treatment in a patient with adult-onset TK2 deficiency: A case report.

Mitochondrion
2024

CHCHD10S59L/+ mouse model: Behavioral and neuropathological features of frontotemporal dementia.

Neurobiology of disease
2024

DELE1 promotes translation-associated homeostasis, growth, and survival in mitochondrial myopathy.

bioRxiv : the preprint server for biology
2024

Pseudouridine synthase 1 regulates erythropoiesis via transfer RNAs pseudouridylation and cytoplasmic translation.

iScience
2024

Clinical, biochemical and molecular characterization of a new case with FDX2-related mitochondrial disorder: Potential biomarkers and treatment options.

JIMD reports
2024

Mitochondrial myopathies diagnosed in adulthood: clinico-genetic spectrum and long-term outcomes.

Brain communications
2023

A case of mitochondrial myopathy and chronic progressive external ophthalmoplegia.

Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
2025

Research progress of RNA pseudouridine modification in nervous system.

The International journal of neuroscience
2024

A case of exacerbated encephalopathy with stroke-like episodes and lactic acidosis triggered by metformin in a patient with MELAS.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2023

Have one's view of the important overshadowed by the trivial: chronic progressive external ophthalmoplegia combined with unilateral facial nerve injury: a case report and literature review.

Frontiers in neurology
2024

A clinical approach to diagnosis and management of mitochondrial myopathies.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
2023

Improvement of Intestinal Pseudo-Obstruction by Total Parenteral Nutrition in a Young Woman With Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis, and Stroke-Like Episodes: A Case Report.

Cureus
2023

Clinical Spectrum of Biopsy Proven Mitochondrial Myopathy.

Neurology India
2023

Weaning difficulty after severe pneumonia in adult-onset mitochondrial myopathy with A3243G mutation in the mitochondrial tRNA gene: A case report.

Heliyon
2023

Prominent muscle involvement in a familial form of mitochondrial disease due to a COA8 variant.

Frontiers in genetics
2023

Progressive external ophthalmoplegia - A case report.

Indian journal of pathology & microbiology
2023

A new family with a case of severe early-onset muscle fatigue and a peculiar maternally inherited painful swelling in chewing muscles associated with homoplasmic m.15992A>T mutation in mitochondrial tRNAPro.

Neuromuscular disorders : NMD
2023

Lowered oxidative capacity in spinal muscular atrophy, Jokela type; comparison with mitochondrial muscle disease.

Frontiers in neurology
2023

Autosomal Recessive Mitochondrial Myopathy due to MICU-1 Variants.

Annals of Indian Academy of Neurology
2023

Interactions of mitochondrial and skeletal muscle biology in mitochondrial myopathy.

The Biochemical journal
2023

Ryanodine receptor type 1 content decrease-induced endoplasmic reticulum stress is a hallmark of myopathies.

Journal of cachexia, sarcopenia and muscle
2024

Mitochondrial myopathy without extraocular muscle involvement: a unique clinicopathologic profile.

Journal of neurology
2023

CHCHD10 mutations induce tissue-specific mitochondrial DNA deletions with a distinct signature.

Human molecular genetics
2024

Altered Neurovascular Coupling in Patients With Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS): A Combined Resting-State fMRI and Arterial Spin Labeling Study.

Journal of magnetic resonance imaging : JMRI
2023

Reversible cardiac function and left ventricular hypertrophy in a Chinese man with mitochondrial myopathy: a case report.

BMC cardiovascular disorders
2023

Discovery of a First-in-Class CD38 Inhibitor for the Treatment of Mitochondrial Myopathy.

Journal of medicinal chemistry
2024

Myopathy and Ophthalmologic Abnormalities in Association With Multiple Skeletal Muscle Mitochondrial DNA Deletions.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
2023

Infraclavicular Catheter in MELAS Syndrome for Analgesic Purposes.

Neurology India
2023

Mitochondrial dysfunction characterized in human induced pluripotent stem cell disease models in MELAS syndrome: A brief summary.

Mitochondrion
2023

Treatment of a patient with severe lactic acidosis and multiple organ failure due to mitochondrial myopathy: A case report.

World journal of clinical cases
2023

Precision therapy for a medically actionable ATP1A3 variant from a genomic medicine program in an underserved population.

Molecular genetics & genomic medicine
2023

Glutamine metabolism in diseases associated with mitochondrial dysfunction.

Molecular and cellular neurosciences
2023

Α rare case of myopathy, lactic acidosis, and severe rhabdomyolysis, due to a homozygous mutation of the ferredoxin-2 (FDX2) gene.

American journal of medical genetics. Part A
2023

Neuropathological hallmarks in autopsied cases with mitochondrial diseases caused by the mitochondrial 3243A>G mutation.

Brain pathology (Zurich, Switzerland)
2023

Patent foramen ovale leading to mismanagement in a mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes patient.

Clinical case reports
2023

A case of mitochondrial DNA depletion syndrome type 11 - expanding the genotype and phenotype.

Neuromuscular disorders : NMD
2023

Clinical and bi-genomic DNA findings of patients suspected to have mitochondrial diseases.

Frontiers in genetics
2023

Exercise testing and prescription in patients with inborn errors of muscle energy metabolism.

Journal of inherited metabolic disease
2024

The impacts of the mitochondrial myopathy-associated G58R mutation on the dynamic structural properties of CHCHD10.

Journal of biomolecular structure & dynamics
2023

The acute effect of different NAD+ precursors included in the combined metabolic activators.

Free radical biology & medicine
2023

Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.

Neurology
2023

Clinical, Genetic, and Histological Characterization of Patients with Rare Neuromuscular and Mitochondrial Diseases Presenting with Different Cardiomyopathy Phenotypes.

International journal of molecular sciences
2023

Mitochondrial Mutations Can Alter Neuromuscular Transmission in Congenital Myasthenic Syndrome and Mitochondrial Disease.

International journal of molecular sciences
2023

A coordinated multiorgan metabolic response contributes to human mitochondrial myopathy.

EMBO molecular medicine
2023

Case report: Muscle involvement in a Chinese patient with TRNT1-related disorder.

Frontiers in pediatrics
2024

Test-retest reliability of three life balance measures in people with neuromuscular disease: the activity card sort-NL, the activity calculator, and the occupational balance questionnaire.

Disability and rehabilitation
2023

Frontotemporal Dementia-Related V57E Mutation Impairs Mitochondrial Function and Alters the Structural Properties of CHCHD10.

ACS chemical neuroscience
2023

Mitochondrial Myopathy in a 21-Year-Old Man Presenting With Bilateral Lower Extremity Weakness and Swelling.

Journal of primary care & community health
2023

CHCHD2 and CHCHD10-related neurodegeneration: molecular pathogenesis and the path to precision therapy.

Biochemical Society transactions
2023

Primary mitochondrial disease as a rare cause of unclear breathlessness and distinctive performance degradation - a case report.

BMC pulmonary medicine
2023

Serum GDF-15 Levels Accurately Differentiate Patients with Primary Mitochondrial Myopathy, Manifesting with Exercise Intolerance and Fatigue, from Patients with Chronic Fatigue Syndrome.

Journal of clinical medicine
2023

Bilateral plaque like macular atrophy and pigmentary retinopathy in an infant with a missense mutation in the MFF gene.

Ophthalmic genetics
2023

Restoration of mitochondrial function through activation of hypomodified tRNAs with pathogenic mutations associated with mitochondrial diseases.

Nucleic acids research
2023

TEFM variants impair mitochondrial transcription causing childhood-onset neurological disease.

Nature communications
2023

Depletion of plasma thymidine results in growth retardation and mitochondrial myopathy in mice overexpressing human thymidine phosphorylase.

The Journal of biological chemistry
2022

A Patient with MELAS Syndrome Carried an M.3243A>G Mutation in Mitochondrial DNA and Multiple Nuclear Genetic Variants: A Case Report.

Iranian journal of public health
2023

Unexplained dyspnea linked to mitochondrial myopathy following military deployment to Southwest Asia and Afghanistan.

Physiological reports
2023

Use of Elamipretide in patients assigned treatment in the compassionate use program: Case series in pediatric patients with rare orphan diseases.

JIMD reports
2023

Generalized Muscular Hypermetabolism Caused by Mitochondrial Myopathy Shown on 18 F-FDG PET/CT.

Clinical nuclear medicine
2023

Lactate metabolism is essential in early-onset mitochondrial myopathy.

Science advances
2022

Psychometric performance of the Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) in a randomized, double-blind, placebo-controlled crossover study in subjects with mitochondrial disease.

Journal of patient-reported outcomes
2022

Retrograde response to mitochondrial dysfunctions associated to LOF variations in FLAD1 exon 2: unraveling the importance of RFVT2.

Free radical research
2022

Enzymatically dissociated muscle fibers display rapid dedifferentiation and impaired mitochondrial calcium control.

iScience
2022

The Cytokine Growth Differentiation Factor-15 and Skeletal Muscle Health: Portrait of an Emerging Widely Applicable Disease Biomarker.

International journal of molecular sciences
2022

Data-independent acquisition-based quantitative proteomic analysis of m.3243A>G MELAS reveals novel potential pathogenesis and therapeutic targets.

Medicine
2022

Long term follow-up in two siblings with Sengers syndrome: Case report.

Italian journal of pediatrics
2022

Splicing variants in NARS2 are associated with milder phenotypes and intra-familial variability.

European journal of medical genetics
2022

Impediments to Heart Transplantation in Adults With MELASMT-TL1:m.3243A>G Cardiomyopathy.

Journal of the American College of Cardiology
2022

VARS2 gene mutation leading to overall developmental delay in a child with epilepsy: A case report.

World journal of clinical cases
2022

Independent origin for m.3243A>G mitochondrial mutation in three Venezuelan cases of MELAS syndrome.

Clinical biochemistry
2022

Acipimox in Mitochondrial Myopathy (AIMM): study protocol for a randomised, double-blinded, placebo-controlled, adaptive design trial of the efficacy of acipimox in adult patients with mitochondrial myopathy.

Trials
2022

Case report: Novel SCN4A variant associated with a severe congenital myasthenic syndrome/myopathy phenotype.

Frontiers in pediatrics
2022

Expanding the clinicopathological-genetic spectrum of glycogen storage disease type IXd by a Chinese neuromuscular center.

Frontiers in neurology
2022

Successful Anesthetic Management of Mitochondrial Myopathy and Hypertrophic Obstructive Cardiomyopathy in a Child With Senger Syndrome.

American journal of therapeutics
2022

Primary mitochondrial myopathy: 12-month follow-up results of an Italian cohort.

Journal of neurology
2022

Reversible cerebral artery constriction accompanied with stroke-like episode in MELAS: A case series.

Journal of the neurological sciences
2022

Calorie Restriction Rescues Mitochondrial Dysfunction in Adck2-Deficient Skeletal Muscle.

Frontiers in physiology
2022

The roles of PARK gene family in myopathy.

Yi chuan = Hereditas
2022

Transcriptome analysis from muscle biopsy tissues in late-onset myopathies identifies potential biomarkers correlating to muscle pathology.

Neuromuscular disorders : NMD
2022

Novel TOP3A Variant Associated With Mitochondrial Disease: Expanding the Clinical Spectrum of Topoisomerase III Alpha-Related Diseases.

Neurology. Genetics
2022

Successful catheter ablation of a left posterolateral accessory bypass tract and periinterventional management in a patient with MELAS syndrome.

Herzschrittmachertherapie & Elektrophysiologie
2022

Intrinsically disordered proteins and proteins with intrinsically disordered regions in neurodegenerative diseases.

Biophysical reviews
2022

OMA1 mediates local and global stress responses against protein misfolding in CHCHD10 mitochondrial myopathy.

The Journal of clinical investigation
2022

Screening and prevalence of cardiac abnormalities on electro- and echocardiography in a large cohort of patients with mitochondrial disease.

Molecular genetics and metabolism
2022

Remimazolam anesthesia for transcatheter mitral valve repair in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome: a case report.

JA clinical reports
2022

[A case of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) complicated by chronic intestinal pseudo-obstruction].

Rinsho shinkeigaku = Clinical neurology
2022

Features and diagnostic value of body composition in patients with late-onset multiple acyl-CoA dehydrogenase deficiency.

Acta neurologica Belgica
2022

Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome mimicking herpes simplex encephalitis: A case report.

Radiology case reports
2022

Clinicopathologic Profiles of Sporadic Late-Onset Nemaline Myopathy: Practical Importance of Anti-α-Actinin Immunostaining.

Neurology(R) neuroimmunology & neuroinflammation
2022

Disoriented collagen fibers and disorganized, fibrotic orbicularis oris muscle fiber with mitochondrial myopathy in non-syndromic cleft lip.

Archives of oral biology
2022

Rapid identification of human muscle disease with fibre optic Raman spectroscopy.

The Analyst
2022

Current perspectives on mitochondrial dysfunction in migraine.

The European journal of neuroscience
2022

A Single mtDNA Deletion in Association with a LMNA Gene New Frameshift Variant: A Case Report.

Journal of neuromuscular diseases
2022

[Diagnosis of a child with mitochondrial myopathy and cerebellar atrophy with ataxia due to compound heterozygous variants of MSTO1 gene].

Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
2022

Atypical mitochondrial myopathy - A clinical enigma deciphered by muscle biopsy.

Indian journal of pathology & microbiology
2022

Beneficial Effects of Flavonoids on Skeletal Muscle Health: A Systematic Review and Meta-Analysis.

Journal of medicinal food
2022

Decompensation of cardiorespiratory function and emergence of anemia during pregnancy in a case of mitochondrial myopathy, lactic acidosis, and sideroblastic anemia 2 with compound heterozygous YARS2 pathogenic variants.

American journal of medical genetics. Part A
2022

Novel truncating variants in FGD1 detected in two Danish families with Aarskog-Scott syndrome and myopathic features.

American journal of medical genetics. Part A
2022

Anesthetic Management of the Patient with Mitochondrial Disease: A Review of Current Best Evidence.

AANA journal
2022

Automatic Recognition of Ragged Red Fibers in Muscle Biopsy from Patients with Mitochondrial Disorders.

Healthcare (Basel, Switzerland)
2022

Biallelic Variants in ENDOG Associated with Mitochondrial Myopathy and Multiple mtDNA Deletions.

Cells
Ver todos os 827 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Miopatia mitocondrial.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Miopatia mitocondrial

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Statins in Genetic Myopathies: A Retrospective Analysis of Safety and Tolerability.
    Neurology. Clinical practice· 2026· PMID 41726791mais citado
  2. Fusion Between Control Mesoangioblasts and mtDNA-Mutant Myotubes Preserves Myotube Morphology and Mitochondrial Network Organization.
    International journal of molecular sciences· 2026· PMID 41683780mais citado
  3. Loss of Myofilaments in Gastrointestinal Smooth Muscle: A Novel Pathological Finding in MELAS-Associated Chronic Intestinal Pseudo-Obstruction.
    Neurogastroenterology and motility· 2026· PMID 41681036mais citado
  4. A Case of Mitochondrial Myopathy, Lactic Acidosis and Sideroblastic Anemia (MLASA Syndrome) and Long QT Interval in a 10-Year-Old Saudi Child.
    Saudi journal of medicine & medical sciences· 2026· PMID 41675948mais citado
  5. Exploring Outcome Measures for Mitochondrial Myopathies; Insights From a Longitudinal Study on TK2 Deficiency.
    Journal of inherited metabolic disease· 2026· PMID 41571587mais citado
  6. Loss of STARD7 Impairs Mitochondrial Phospholipid Homeostasis and Contributes to Mitochondrial Myopathy.
    FASEB J· 2026· PMID 41989333recente
  7. From Initiation to Elongation: eIF3 as a Dual-Phase Guardian of Mitochondrial Integrity and Protein Homeostasis in Skeletal Muscle.
    FASEB J· 2026· PMID 41989318recente
  8. Perilipin 5 enhances glycogen storage and mitigates excessive fatty acid oxidation in skeletal muscle to alleviate mitochondrial impairment.
    Biochim Biophys Acta Mol Cell Res· 2026· PMID 41962775recente
  9. Transforming the natural course of infantile onset thymidine kinase 2 deficiency through early nucleoside replacement therapy.
    J Neuromuscul Dis· 2026· PMID 41944166recente
  10. Anaesthethic management on a pediatric patient with Sengers syndrome. Case report.
    Rev Esp Anestesiol Reanim (Engl Ed)· 2026· PMID 41825688recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:206966(Orphanet)
  2. MONDO:0009637(MONDO)
  3. GARD:20371(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Artigo Wikipedia(Wikipedia)
  7. Q6881881(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Miopatia mitocondrial
Compêndio · Raras BR

Miopatia mitocondrial

ORPHA:206966 · MONDO:0009637
CID-10
G71.3 · Miopatia mitocondrial não classificada em outra parte
CID-11
Ensaios
6 ativos
MedGen
UMLS
C0162670
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades